Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:01:52 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 11:03:14 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10717238.5

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH
G2 O,S,NH
G3 NH,NH2,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 11:03:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     27 TO ITERATE

100.0% PROCESSED      27 ITERATIONS                                9 ANSWERS
SEARCH TIME: 00.00.01

L2             9 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.42     155.84

FILE 'MARPAT' ENTERED AT 11:03:48 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6709645 23 MAR 2004
DE   10335606 11 MAR 2004
EP    1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 11:03:53 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   1779 TO ITERATE

100.0% PROCESSED    1779 ITERATIONS                               1 ANSWERS
SEARCH TIME: 00.00.19

L3             1 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   109.42     265:26

FILE 'CAOLD' ENTERED AT 11:04:23 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)
```

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:04:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L4 9 SEA SSS FUL L1

L5 0 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	421.52

FILE 'CAPLUS' ENTERED AT 11:04:34 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 11:01:52 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 11:03:14 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2           9 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 11:03:48 ON 28 APR 2004
L3           1 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 11:04:23 ON 28 APR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 11:04:28 ON 28 APR 2004
L4           9 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 11:04:28 ON 28 APR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:04:34 ON 28 APR 2004

=> s l2
L6           2 L2

=> s l3
L7           1 L3

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:256240  CAPLUS
DN   136:279118
TI   Preparation and use of amido-hydroxy-carboxylic acid integrin antagonists
IN   Rogers, Thomas; Penning, Thomas D.; Jiang, Lan; Devadas, Balekudru;
     Ruminiski, Peter; Chester, Yuan; Vancamp, Jennifer
PA   Pharmacia Corporation, USA
SO   PCT Int. Appl., 64 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002026717      A2    20020404      WO 2001-US30189  20010927
     WO 2002026717      C1    20021227
     WO 2002026717      A3    20020912
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
```

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2000-235616PP 20000927
US 2000-241656PP 20001010

US 2002072500 A1 20020613 US 2001-963927 20010926
US 2000-235616PP 20000927
US 2000-241656PP 20001010

AU 2001093131 A5 20020408 AU 2001-93131 20010927
US 2000-235616PP 20000927
US 2000-241656PP 20001010
WO 2001-US30189W 20010927

EP 1322623 A2 20030702 EP 2001-973568 20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2000-235616PP 20000927
US 2000-241656PP 20001010
WO 2001-US30189W 20010927

JP 2004509950 T2 20040402 JP 2002-531101 20010927
US 2000-235616PP 20000927
US 2000-241656PP 20001010
WO 2001-US30189W 20010927

US 2004024062 A1 20040205 US 2003-381825 20030327
WO 2001-US30189W 20010927

OS MARPAT 136:279118

IT **406682-41-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of amido-hydroxy-carboxylic acid integrin antagonists)

RN 406682-41-5 CAPLUS

CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 406682-40-4
CMF C17 H21 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **406682-46-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation and use of amido-hydroxy-carboxylic acid integrin antagonists)
RN 406682-46-0 CAPLUS
CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl,

arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give intermediate lactone II isolated as the TFA salt. The desired hydroxy acid was obtained by hydrolysis and isolation at a final pH of approx. 8. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256040 CAPLUS
DN 136:279325
TI Preparation and use of amido-lactone integrin antagonists
IN Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas; Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026227	A1	20020404	WO 2001-US30194	20010927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2000-235617PP	20000927
				US 2000-241633PP	20001010
	US 2002045645	A1	20020418	US 2001-963926	20010926
	US 6720327	B2	20040413		
				US 2000-235617PP	20000927
				US 2000-241633PP	20001019
	EP 1320363	A1	20030625	EP 2001-975450	20010927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-235617PP	20000927
				US 2000-241633PP	20001010
				WO 2001-US30194W	20010927
	US 2004019206	A1	20040129	US 2003-381831	20030327
				WO 2001-US30194W	20010927

OS MARPAT 136:279325

IT **406682-40-4P 406682-41-5P 406682-46-0P**
406703-18-2P 406703-27-3P 406703-30-8P
406703-31-9P 406703-35-3P 406703-36-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of amido-lactone integrin antagonists)

RN 406682-40-4 CAPLUS

CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406682-41-5 CAPLUS

CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 406682-40-4
CMF C17 H21 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 406682-46-0 CAPLUS
CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406703-18-2 CAPLUS
CN Benzamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 406682-46-0
CMF C17 H21 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 406703-27-3 CAPLUS
CN Benzamide, 3-[(5-fluoro-1,4,5,6-tetrahydro-2-pyrimidinyl)amino]-N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406703-30-8 CAPLUS
CN Benzamide, 3-[(4,5-dihydro-1H-imidazol-2-yl)amino]-N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406703-31-9 CAPLUS
CN Benzamide, 3-[(4,5-dihydro-1H-imidazol-2-yl)amino]-N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 406703-30-8
CMF C16 H19 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 406703-35-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406703-36-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-oxo-2-[[(3S)-tetrahydro-5-oxo-3-furanyl]amino]ethyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-, trifluoroacetate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 406703-35-3
CMF C16 H20 N6 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d hnis
'HNIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
```

information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d his

(FILE 'HOME' ENTERED AT 11:01:52 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:03:14 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 9 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 11:03:48 ON 28 APR 2004
L3 1 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 11:04:23 ON 28 APR 2004
S L1

FILE 'REGISTRY' ENTERED AT 11:04:28 ON 28 APR 2004
L4 9 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 11:04:28 ON 28 APR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:04:34 ON 28 APR 2004
L6 2 S L2
L7 1 S L3

=> d l7 fbib hitstr abs total

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256040 CAPLUS
DN **136:279325**
TI Preparation and use of amido-lactone integrin antagonists
IN Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas; Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002026227	A1	20020404	WO 2001-US30194	20010927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2000-235617PP 20000927
				US 2000-241633PP 20001010
US 2002045645	A1	20020418	US 2001-963926	20010926
US 6720327	B2	20040413		
				US 2000-235617PP 20000927
				US 2000-241633PP 20001019
EP 1320363	A1	20030625	EP 2001-975450	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-235617PP 20000927
				US 2000-241633PP 20001010
				WO 2001-US30194W 20010927
US 2004019206	A1	20040129	US 2003-381831	20030327
				WO 2001-US30194W 20010927

OS MARPAT 136:279325

GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected

with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.93	434.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.08	-2.08

STN INTERNATIONAL LOGOFF AT 11:05:33 ON 28 APR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:19:33 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10717238.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH
G2 O,S,NH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 10:20:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 10:20:16 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6709645 23 MAR 2004
DE 10335606 11 MAR 2004
EP 1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 10:20:23 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 6715 TO ITERATE

66.8% PROCESSED 4485 ITERATIONS 0 ANSWERS

95.5% PROCESSED 6413 ITERATIONS 2 ANSWERS

100.0% PROCESSED 6715 ITERATIONS (2 INCOMPLETE) 4 ANSWERS
SEARCH TIME: 00.00.44

L3 4 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.84	265.47

FILE 'CAOLD' ENTERED AT 10:21:28 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent

assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:21:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

L5 0 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	421.73

FILE 'CAPLUS' ENTERED AT 10:21:42 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:19:33 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 10:19:45 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 10:20:16 ON 28 APR 2004
L3           4 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 10:21:28 ON 28 APR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 10:21:34 ON 28 APR 2004
L4           0 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 10:21:36 ON 28 APR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:21:42 ON 28 APR 2004

=> s l3
L6           4 L3

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:256040  CAPLUS
DN   136:279325
TI   Preparation and use of amido-lactone integrin antagonists
IN   Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas;
     Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA   Pharmacia Corporation, USA
SO   PCT Int. Appl., 88 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002026227      A1    20020404      WO 2001-US30194  20010927
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           US 2000-235617PP 20000927
                                           US 2000-241633PP 20001010
     US 2002045645      A1    20020418      US 2001-963926   20010926
     US 6720327         B2    20040413
                                           US 2000-235617PP 20000927
                                           US 2000-241633PP 20001019
     EP 1320363         A1    20030625      EP 2001-975450   20010927
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2000-235617PP 20000927
US 2000-241633PP 20001010
WO 2001-US30194W 20010927
US 2004019206 A1 20040129 US 2003-381831 20030327
WO 2001-US30194W 20010927

OS MARPAT 136:279325

GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:338525 CAPLUS
DN **134:353248**
TI Novel heterocyclic compounds and their use as medicines
IN Auvin, Serge; Chabrier De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032654	A2	20010510	WO 2000-FR3067	20001103
	WO 2001032654	A3	20010927		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				FR 1999-13858	A 19991105
				FR 2000-6535	A 20000523
	FR 2800737	A1	20010511	FR 1999-13858	19991105
	FR 2809398	A1	20011130	FR 2000-6535	20000523
	FR 2809398	B3	20020726		
	BR 2000015315	A	20020625	BR 2000-15315	20001103
				FR 1999-13858	A 19991105
				FR 2000-6535	A 20000523
				WO 2000-FR3067	W 20001103
	EP 1233962	A2	20020828	EP 2000-974646	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				FR 1999-13858	A 19991105
				FR 2000-6535	A 20000523
				WO 2000-FR3067	W 20001103
	JP 2003513092	T2	20030408	JP 2001-534805	20001103
				FR 1999-13858	A 19991105
				FR 2000-6535	A 20000523
				WO 2000-FR3067	W 20001103
	NO 2002002088	A	20020502	NO 2002-2088	20020502
				FR 1999-13858	A 19991105
				FR 2000-6535	A 20000523
				WO 2000-FR3067	W 20001103

OS MARPAT 134:353248
AB Novel heterocyclic derivs. which have calpain inhibiting and/or reactive oxygen species trapping activity (no data) are reported. Thus, (R)-Trolox was treated with (S)-2-aminobutyrolactone hydrochloride, followed by DIBAL reduction to give (2R)-6-hydroxy-N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxamide.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:197524 CAPLUS
DN **128:257704**
TI Preparation of methionine, penicillamine and cysteine-analog containing peptides having immunomodulating activity
IN Bergstrand, Hakan; Eriksson, Tomas; Lindvall, Magnus; Sarnstrand, Bengt
PA Astra Aktiebolag, Swed.; Bergstrand, Hakan; Eriksson, Tomas; Lindvall, Magnus; Sarnstrand, Bengt
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9812219	A1	19980326	WO 1997-SE1554	19970915
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			SE 1996-3468 A	19960923
AU 9744063	A1	19980414	AU 1997-44063	19970915
			SE 1996-3468 A	19960923
			WO 1997-SE1554 W	19970915
ZA 9708472	A	19980323	ZA 1997-8472	19970919
			SE 1996-3468 A	19960923

OS MARPAT 128:257704
GI





I

AB Physiol. active peptides A-R1-R2-R3-(R4)x-B [A = H, protective group, amino acid residue; R1 = Gly, Pro, Asp, Arg, Ala, Ile, Trp, Ser, Cys, Glu, Asn, R8; R2 = Cys, Pro, Ile, Ala, Tyr, Thr, Arg, pipecolic acid, R8; R3 = Cys, R8; R4 = Gly, Phe, Val, Ile, Lys, Pro, Trp, Tyr, Glu, Leu, Met; R5, R6 = independently H, alkyl, alkoxy, aryl; R7 = SOH, SO2H, SO3H, SR9,

SeR9, TeR9; R8 = residue Q, Q1; R9 = H, alkyl, alkoxy, aryl, SR10, SOR10, SO2R10; R10 = H, alkyl, alkoxy; B = OH, NH2, protected O, protected N, amino acid residue; n = 0-4; m = 0-4; x = 0-1; with provisos; the entire peptide contains 3-30 amino acid residues] and salts and homo- and heterodimers thereof are described as compds. for use in therapy as immunomodulatory agents. These peptides are absorbable by the epithelial cell lining in a mammal resulting in a modulated immune response and thereby a therapeutic effect against disease. Thus, a variety of cysteine analog peptides, e.g. I, were prepared by solid-phase methods and tested for immunomodulatory activity in a delayed type hypersensitivity test in mice.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:197519 CAPLUS
DN **128:257699**
TI Preparation of cysteine analog peptides having immunomodulatory effects
IN Bergstrand, Hakan; Eriksson, Tomas; Lindvall, Magnus; Sarnstrand, Bengt
PA Astra Aktiebolag, Swed.; Bergstrand, Hakan; Eriksson, Tomas; Lindvall, Magnus; Sarnstrand, Bengt
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9812214	A1	19980326	WO 1997-SE1548	19970915
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			SE 1996-3461	19960923
AU 9744059	A1	19980414	AU 1997-44059	19970915
			SE 1996-3461	19960923
			WO 1997-SE1548	19970915

OS MARPAT 128:257699
GI







I

AB Physiol. active peptides A-R1-R2-R3-(R4)x-B [A = H, protective group, amino acid residue; R1 = Gly, Pro, Asp, Arg, Ala, Ile, Trp, Ser, Cys, Glu, Asn, R8; R2 = Cys, Pro, Ile, Ala, Tyr, Thr, Arg, pipecolic acid, R8; R3 = Cys, R8; R4 = Gly, Phe, Val, Ile, Pro, Trp, Tyr, Glu, Lys, Leu, Met; R5, R6 = independently H, alkyl, alkoxy, aryl; R7 = SOH, SO2H, SO3H, SR9, SeR9, TeR9; R8 = residue Q, Q1; R9 = H, alkyl, alkoxy, aryl, SR10, SOR10, SO2R10; R10 = H, alkyl, alkoxy; B = OH, NH2, protected O, protected N, amino acid residue; n = 0-4; m = 0-4; x = 0-1; with the provisos that at least one of R1-R3 = R8 and at most one of R1-R3 = Cys; the entire peptide contains 3-30 amino acid residues] and salts and homo- and heterodimers thereof are described as compds. for use in therapy as immunomodulatory agents. These peptides are absorbable by the epithelial cell lining in a mammal resulting in a modulated immune response and thereby a therapeutic effect against disease. Thus, a variety of cysteine analog peptides, e.g. I, were prepared by solid-phase methods and tested for immunomodulatory activity in a delayed type hypersensitivity test in mice.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.04	432.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.77	-2.77

STN INTERNATIONAL LOGOFF AT 10:22:38 ON 28 APR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:07:41 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:08:16 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10717238.6

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH
G2 O,S,NH
G3 NH,NH2,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 11:08:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      14 TO ITERATE

100.0% PROCESSED      14 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L2             0 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     155.42     155.63

FILE 'MARPAT' ENTERED AT 11:08:57 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US     6709645 23 MAR 2004
DE    10335606 11 MAR 2004
EP     1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 11:09:08 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -    2361 TO ITERATE

 99.7% PROCESSED    2353 ITERATIONS                                1 ANSWERS

100.0% PROCESSED    2361 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.26

L3             1 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     109.84     265.47

FILE 'CAOLD' ENTERED AT 11:10:20 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGistRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:10:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

L5 0 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	421.73

FILE 'CAPLUS' ENTERED AT 11:10:31 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 11:07:41 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 11:08:16 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 11:08:57 ON 28 APR 2004
L3           1 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 11:10:20 ON 28 APR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 11:10:26 ON 28 APR 2004
L4           0 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 11:10:27 ON 28 APR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:10:31 ON 28 APR 2004

=> s l3
L6           1 L3

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:256040  CAPLUS
DN   136:279325
TI   Preparation and use of amido-lactone integrin antagonists
IN   Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas;
     Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA   Pharmacia Corporation, USA
SO   PCT Int. Appl., 88 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2002026227      A1   20020404      WO 2001-US30194  20010927
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                          US 2000-235617PP 20000927
                                          US 2000-241633PP 20001010
```

US 2002045645	A1	20020418	US 2001-963926	20010926
US 6720327	B2	20040413		
			US 2000-235617PP	20000927
			US 2000-241633PP	20001019
EP 1320363	A1	20030625	EP 2001-975450	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-235617PP	20000927
			US 2000-241633PP	20001010
			WO 2001-US30194W	20010927
US 2004019206	A1	20040129	US 2003-381831	20030327
			WO 2001-US30194W	20010927

OS MARPAT 136:279325

GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5

integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.98	424.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

STN INTERNATIONAL LOGOFF AT 11:10:59 ON 28 APR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:33:40 ON 28 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:33:51 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10717238.2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH

G2 O,S,NH

G3 NH,NH2,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 10:34:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   3987 TO ITERATE

100.0% PROCESSED    3987 ITERATIONS                          41 ANSWERS
SEARCH TIME: 00.00.01

L2           41 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.63

FILE 'MARPAT' ENTERED AT 10:34:24 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US     6709645 23 MAR 2004
DE    10335606 11 MAR 2004
EP     1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 10:34:30 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -  48637 TO ITERATE

 19.6% PROCESSED    9528 ITERATIONS  (     1 INCOMPLETE)      16 ANSWERS

 37.5% PROCESSED   18246 ITERATIONS  (     1 INCOMPLETE)      26 ANSWERS

 67.1% PROCESSED   32622 ITERATIONS  (     2 INCOMPLETE)      49 ANSWERS

 77.8% PROCESSED   37841 ITERATIONS  (     2 INCOMPLETE)      55 ANSWERS

 84.9% PROCESSED   41276 ITERATIONS  (     2 INCOMPLETE)      63 ANSWERS

 92.1% PROCESSED   44808 ITERATIONS  (     3 INCOMPLETE)      65 ANSWERS

 94.6% PROCESSED   45988 ITERATIONS  (     3 INCOMPLETE)      66 ANSWERS

 97.9% PROCESSED   47636 ITERATIONS  (     3 INCOMPLETE)      71 ANSWERS

100.0% PROCESSED   48637 ITERATIONS  (     3 INCOMPLETE)      71 ANSWERS
SEARCH TIME: 00.02.45
```

L3 71 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 111.52 267.15

FILE 'CAOLD' ENTERED AT 10:37:55 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGistRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:38:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3987 TO ITERATE

100.0% PROCESSED 3987 ITERATIONS 41 ANSWERS
SEARCH TIME: 00.00.01

L4 41 SEA SSS FUL L1

L5 0 L4

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.42 423.41

FILE 'CAPLUS' ENTERED AT 10:38:08 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:33:40 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 10:33:51 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 41 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:34:24 ON 28 APR 2004
L3 71 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:37:55 ON 28 APR 2004
S L1

FILE 'REGISTRY' ENTERED AT 10:38:02 ON 28 APR 2004
L4 41 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:38:03 ON 28 APR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:38:08 ON 28 APR 2004

=> s l2
L6 15 L2

=> s l3
L7 71 L3

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256040 CAPLUS
DN 136:279325
TI Preparation and use of amido-lactone integrin antagonists
IN Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas; Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002026227	A1	20020404	WO 2001-US30194	20010927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2000-235617PP	20000927
			US 2000-241633PP	20001010
US 2002045645	A1	20020418	US 2001-963926	20010926
US 6720327	B2	20040413		
			US 2000-235617PP	20000927
			US 2000-241633PP	20001019
EP 1320363	A1	20030625	EP 2001-975450	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-235617PP	20000927
			US 2000-241633PP	20001010
			WO 2001-US30194W	20010927
US 2004019206	A1	20040129	US 2003-381831	20030327
			WO 2001-US30194W	20010927

OS MARPAT 136:279325
IT **406703-74-0 406703-76-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation and use of amido-lactone integrin antagonists)
RN 406703-74-0 CAPLUS
CN Glycine, N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 406703-76-2 CAPLUS
CN Glycine, N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for

the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:521916 CAPLUS
DN 135:107152
TI Preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists
IN Widdowson, Katherine Louisa; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Philip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corp., USA
SO U.S., 51 pp., Cont.-in-part of U.S. 58,86,044.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6262113	B1	20010717	US 1998-125279	19980814
				US 1996-641990 A219960320	
				WO 1996-US13632W	19960821
	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B219950217	
	WO 9729743	A1	19970821	WO 1996-US13632	19960821
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				WO 1996-US2260 A 19960216	
				WO 1996-US2260 A219960216	
	US 2002128321	A1	20020912	US 2001-871076	20010531
				WO 1996-US13632W	19960821
				US 1998-125279 A319980814	

PATENT FAMILY INFORMATION:
FAN 1996:643902

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9625157	A1	19960822	WO 1996-US2260	19960216
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-390260 A219950217	
	EP 809492	A1	19971203	EP 1996-906547	19960216
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
				US 1995-390260 A 19950217	
				WO 1996-US2260 W 19960216	
	JP 11503110	T2	19990323	JP 1996-525199	19960216
				US 1995-390260 A 19950217	
				WO 1996-US2260 W 19960216	
	CA 2432662	AA	19970821	CA 1996-2432662	19960821
				WO 1996-US2260 A 19960216	
				CA 1996-2245927A319960821	
	WO 9729743	A1	19970821	WO 1996-US13632	19960821
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG,				

KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG

			WO 1996-US2260 A	19960216
			WO 1996-US2260 A2	19960216
AU 9669007	A1	19970902	AU 1996-69007	19960821
AU 725456	B2	20001012		
			WO 1996-US2260 A	19960216
			WO 1996-US13632W	19960821
EP 896531	A1	19990217	EP 1996-929723	19960821
R: AT, ES, GR, LU, SE, MC, PT, IE, SI, LT, LV, FI				
			WO 1996-US2260 W	19960216
			WO 1996-US13632W	19960821
CN 1215990	A	19990505	CN 1996-180245	19960821
			WO 1996-US2260 A	19960216
JP 2000504722	T2	20000418	JP 1997-529318	19960821
			WO 1996-US2260 W	19960216
			WO 1996-US13632W	19960821
NZ 316710	A	20000526	NZ 1996-316710	19960821
			WO 1996-US2260 A	19960216
			WO 1996-US13632W	19960821
BR 9612779	A	20001024	BR 1996-12779	19960821
			WO 1996-US2260 A	19960216
			WO 1996-US13632W	19960821
US 6005008	A	19991221	US 1997-894291	19970815
			WO 1996-US2260 W	19960216
US 6211373	B1	20010403	US 1998-111663	19980708
			US 1995-390260 B1	19950217
			WO 1996-US2260 W	19960216
			US 1996-641990 A3	19960320
			US 1996-701299 A3	19960821
NO 9803737	A	19981014	NO 1998-3737	19980814
			US 1995-390260 A	19950217
			WO 1996-US2260 W	19960216
US 6180675	B1	20010130	US 1999-240354	19990129
			US 1995-390260 B2	19950217
			WO 1996-US2260 A2	19960216
			US 1996-641990 A3	19960320

FAN 1998:123975

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806262	A1	19980219	WO 1997-US14825	19970815
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1996-23991P P	19960815
	CA 2245927	AA	19970821	CA 1996-2245927	19960821
				US 1996-23991P P	19960815
	EP 920253	A1	19990609	EP 1997-939515	19970815
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1996-23991P P	19960815
				WO 1997-US14825W	19970815
	JP 2001527519	T2	20011225	JP 1998-510117	19970815
				US 1996-23991P P	19960815
				WO 1997-US14825W	19970815

FAN 1998:479029

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5780483	A	19980714	US 1996-701299	19960821
			US 1995-390260 B219950217	
			US 1996-641990 A219960320	
US 5886044	A	19990323	US 1996-641990	19960320
			US 1995-390260 B219950217	
US 6211373	B1	20010403	US 1998-111663	19980708
			US 1995-390260 B119950217	
			WO 1996-US2260 W	19960216
			US 1996-641990 A319960320	
			US 1996-701299 A319960821	

FAN 1999:205323

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5886044	A	19990323	US 1996-641990	19960320
			US 1995-390260 B219950217	
US 5780483	A	19980714	US 1996-701299	19960821
			US 1995-390260 B219950217	
			US 1996-641990 A219960320	
US 6211373	B1	20010403	US 1998-111663	19980708
			US 1995-390260 B119950217	
			WO 1996-US2260 W	19960216
			US 1996-641990 A319960320	
			US 1996-701299 A319960821	
US 6262113	B1	20010717	US 1998-125279	19980814
			US 1996-641990 A219960320	
			WO 1996-US13632W	19960821
US 6180675	B1	20010130	US 1999-240354	19990129
			US 1995-390260 B219950217	
			WO 1996-US2260 A219960216	
			US 1996-641990 A319960320	

OS MARPAT 135:107152

IT **182499-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists)

RN 182499-00-9 CAPLUS

CN Glycine, N-[3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; X = O; X1 = O, S; R1 = H, halo, NO2, etc.; two R1 moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; s = 1-3; Y = H, halo, NO2, etc.; two Y moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; n, m = 1-3], useful for treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor, were prepared Thus, reacting Me 4-amino-3-hydroxybenzoate with Ph isocyanate afforded 90% I [X = O; R = OH; R1 = 4-CO2Me; m = 1; Y = H]. All of the exemplified compds. I showed an IC50 from about 45 to about < 1 μg/mL against IL-8 receptor binding. All of these compds. were also found to be inhibitors of Gro-α binding at about the same level.

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:900438 CAPLUS
DN 134:56482
TI Preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists
IN Benson, Gregory Martin; Hertzberg, Robert P.; Jurewicz, Anthony J.; Rutledge, Melvin Clarence; Veber, Daniel F.; Widdowson, Katherine L.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000076495	A1	20001221	WO 2000-US16499	20000615
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-139675PP	19990616
BR 2000010802	A	20020219	BR 2000-10802	20000615
			US 1999-139675PP	19990616
			WO 2000-US16499W	20000615
EP 1185261	A1	20020313	EP 2000-942843	20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1999-139675PP	19990616
			WO 2000-US16499W	20000615
JP 2003501459	T2	20030114	JP 2001-502828	20000615
			US 1999-139675PP	19990616
			WO 2000-US16499W	20000615

AU 766083	B2	20031009	AU 2000-57413	20000615
			US 1999-139675PP	19990616
			WO 2000-US16499W	20000615
ZA 2001009479	A	20021118	ZA 2001-9479	20011116
			US 1999-139675PP	19990616
NO 2001006053	A	20011211	NO 2001-6053	20011211
			US 1999-139675PP	19990616
			WO 2000-US16499W	20000615

OS MARPAT 134:56482

IT **182499-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists)

RN 182499-00-9 CAPLUS

CN Glycine, N-[3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxybenzoyl]-(9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; X = O, S; R = any functional moiety having an ionizable H and pKa of ≤ 10; R1 = H, halo, NO2, etc.; two R1 moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; s = 1-3; Y = H, halo, NO2, etc.; two Y moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; n, m = 1-3], useful for treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor, were prepared Thus, reacting Me 4-amino-3-hydroxybenzoate with Ph isocyanate afforded 90% I [X = O; R = OH; R1 = 4-CO2Me; m = 1; Y = H]. All of the exemplified compds. I showed an IC50 from about 45 to about < 1 μg/mL against IL-8 receptor binding. All of these compds. were also found to be inhibitors of Gro-α binding at about the same level.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:335391 CAPLUS

DN 132:347569

TI Preparation gastrin and cholecystokinin receptor ligands
IN Kalindjian, Sarkis Barret; Buck, Ildiko Maria; Linney, Ian Duncan; Wright, Paul Trevor; McDonald, Iain Mair; Steel, Katherine Isobel Mary; Hull, Robert Antony David; Roberts, Sonia Patricia; Gaffen, John David; Vinter, Jeremy Gilbert; Walker, Martin Keith; Black, James Whyte; Watt, Gillian Fairfull; Harper, Elaine Anne; Shankley, Nigel Paul; Tozer, Matthew John; Dunstone, David John; Pether, Michael John; Lilley, Elliot James; Sykes, David Andrew; Low, Caroline Minli Rachel; Griffin, Eric Peter; Wright, Laurence
PA James Black Foundation Limited, UK
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027823	A1	20000518	WO 1999-GB3733	19991109
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
	CA 2346108	AA	20000518	CA 1999-2346108	19991109
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109
	BR 9915194	A	20010807	BR 1999-15194	19991109
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109
	EP 1178969	A1	20020213	EP 1999-954196	19991109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109
	JP 2002529455	T2	20020910	JP 2000-581003	19991109
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109
	NO 2001002288	A	20010702	NO 2001-2288	20010509
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109
	US 6479531	B1	20021112	US 2001-831385	20010802
				GB 1998-24536 A	19981109
				GB 1999-16786 A	19990716
				WO 1999-GB3733 W	19991109

OS MARPAT 132:347569
IT **269070-25-9P 269074-93-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation gastrin and cholecystokinin receptor ligands)

RN 269070-25-9 CAPLUS

CN Glycine, N-[3-[[[2-cyclohexyl-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 269074-93-3 CAPLUS

CN Glycine, N-[3-[[[2-cyclohexyl-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]carbonyl]amino]benzoyl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 269070-25-9
CMF C31 H40 N4 O4



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



GI



AB Title compds. (I) [wherein X and Y = independently N, N(R5), CH, S, or O; n = 1-4; Z = (NR7)aCO(NR8)b, CONR7CH2CONR8, CO2, CH2CH2, CH=CH, CH2N(R8), or a bond; a and b = independently 0 or 1; Q = R9V (un)substituted phenyl(alkyl); V = CONHSO2Ph, SO2NHCOPh, CH2OH, etc.; R1 = H or (halo)hydrocarbyl where ≤ 3 C atoms may be replaced by N, O, and/or S atoms; R2 = H, Me, Et, Pr, or OH; R3 = H, Me, Et, or Pr; or 2 adjacent R3 groups form a carbocyclic ring when n > 1; or R2 and R3 on the same C atom together = :O ; R4 = (halo)hydrocarbyl where ≤ 2 C atoms may be replaced by N, O, and/or S atoms; R5 = H, Me, Et, Pr, benzyl, OH, or carboxymethyl (esters); R7 and R8 = independently H, Me, Et, Pr, or benzyl; R9 = CH2, CH2CH2, or (un)substituted phenylmethylene; or R8 and R9, together with the adjacent N, form a substituted piperidine or pyrrolidine] and their pharmaceutically acceptable salts were prepared Examples include syntheses and biol. data for 314 compds. Thus, 2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic acid (3-step preparation given) was coupled with 5-aminoisophthalic acid dibenzyl ester (45%), followed by deprotection (98%) to give II. II had pKi of 6.72 for binding at the CCKB mouse cortical membranes and pKb of 6.33 for gastrin antagonist activity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:672798 CAPLUS
DN 131:299691
TI Preparation of heterocyclic glycyl β-alanine derivatives as vitronectin antagonists
IN Chandrakumar, Nizal Samuel; Desai, Bipinchandra Nanubhai; Devadas, Balekudru; Huff, Renee; Khanna, Ish K.; Rao, Shashidhar N.; Rico, Joseph

G.; Rogers, Thomas E.; Ruminski, Peter G.; Russell, Mark Andrew; Yu, Yi; Gasiecki, Alan Frank; Malecha, James W.; Miyashiro, Julie M.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952896	A1	19991021	WO 1999-US4297	19990409
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1998-81394P P	19980410
	US 6689754	B1	20040210	US 1999-289140	19990408
				US 1998-81394P P	19980410
	CA 2326665	AA	19991021	CA 1999-2326665	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	AU 9934499	A1	19991101	AU 1999-34499	19990409
	AU 765294	B2	20030911		
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	EP 1070060	A1	20010124	EP 1999-916119	19990409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	BR 9910119	A	20011009	BR 1999-10119	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	JP 2002511462	T2	20020416	JP 2000-543454	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	RU 2215746	C2	20031110	RU 2000-128033	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	NZ 507292	A	20031219	NZ 1999-507292	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	NO 2000005084	A	20001127	NO 2000-5084	20001009
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409

OS MARPAT 131:299691
IT **247101-76-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic glycyl β-alanine derivs. as vitronectin antagonists)
RN 247101-76-4 CAPLUS
CN Glycine, N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-

pyrimidinyl)amino]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



AB Tile compds. A(CY3Z3)t-Het-CO-V-(CYZ)n-CONR11CHR1(CH2)pCOR [Het = (un)substituted 5-8 membered monocyclic heterocyclic ring containing 1-4 heteroatoms selected from O, N, or S, optionally unsatd. and linked to (CY3Z3)t and CO at the 1- and 3-positions; A = NR5C(:Y1)NR7R8, NR5C(:NR7)Y2, or N:C(NR2R5)(NR7R8), where Y1 = NR2, O, S; R2, R7, R8 = H, alkyl, aryl, amino, etc. or R2 and R8 taken together form an (un)substituted dinitrogen heterocycle; R5 = H, alkyl, alkenyl, alkynyl, benzyl, phenethyl; and Y2 = alkyl, cycloalkyl, bicycloalkyl, aryl, etc.; V = NR6, where R6 = H, alkyl, cycloalkyl, aralkyl, aryl, monocyclic heterocyclyl or R6 together with Y forms a mono-nitrogen-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl or Y and Z together or Y3 and Z3 together form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = X-R3, where X = O, S, or NR4 and R3 and R4 = H, alkyl, sugars, steroids, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.] or their pharmaceutically acceptable salts were prepared as vitronectin antagonists. Thus, 5-[(aminoiminomethyl)amino]-N-[2-[[2-carboxy-1-(3-bromo-5-chloro-2-hydroxyphenyl)ethyl]amino]-2-oxoethyl]-3-pyridinecarboxamide bis(trifluoroacetate) was prepared and showed IC50 = 1.58 nM for inhibition of human vitronectin receptor ($\alpha v\beta 3$).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:205323 CAPLUS
DN 130:267221
TI Preparation of phenylureas as IL-8 receptor antagonists
IN Widdowson, Katherine Louisa; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Phillip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corporation, USA
SO U.S., 43 pp., Cont.-in-part of U.S. Ser. No. 390,260, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B2	19950217
	US 5780483	A	19980714	US 1996-701299	19960821
				US 1995-390260 B2	19950217
				US 1996-641990 A2	19960320
	US 6211373	B1	20010403	US 1998-111663	19980708

				US 1995-390260 B119950217
				WO 1996-US2260 W 19960216
				US 1996-641990 A319960320
				US 1996-701299 A319960821
	US 6262113	B1	20010717	US 1998-125279 19980814
				US 1996-641990 A219960320
				WO 1996-US13632W 19960821
	US 6180675	B1	20010130	US 1999-240354 19990129
				US 1995-390260 B219950217
				WO 1996-US2260 A219960216
				US 1996-641990 A319960320

PATENT FAMILY INFORMATION:

FAN 1996:643902

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9625157	A1	19960822	WO 1996-US2260	19960216
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-390260 A219950217	
	EP 809492	A1	19971203	EP 1996-906547	19960216
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
				US 1995-390260 A 19950217	
				WO 1996-US2260 W 19960216	
	JP 11503110	T2	19990323	JP 1996-525199	19960216
				US 1995-390260 A 19950217	
				WO 1996-US2260 W 19960216	
	CA 2432662	AA	19970821	CA 1996-2432662	19960821
				WO 1996-US2260 A 19960216	
				CA 1996-2245927A319960821	
	WO 9729743	A1	19970821	WO 1996-US13632	19960821
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				WO 1996-US2260 A 19960216	
				WO 1996-US2260 A219960216	
	AU 9669007	A1	19970902	AU 1996-69007	19960821
	AU 725456	B2	20001012		
				WO 1996-US2260 A 19960216	
				WO 1996-US13632W 19960821	
	EP 896531	A1	19990217	EP 1996-929723	19960821
	R: AT, ES, GR, LU, SE, MC, PT, IE, SI, LT, LV, FI				
				WO 1996-US2260 W 19960216	
				WO 1996-US13632W 19960821	
	CN 1215990	A	19990505	CN 1996-180245	19960821
				WO 1996-US2260 A 19960216	
	JP 2000504722	T2	20000418	JP 1997-529318	19960821
				WO 1996-US2260 W 19960216	
				WO 1996-US13632W 19960821	
	NZ 316710	A	20000526	NZ 1996-316710	19960821
				WO 1996-US2260 A 19960216	
				WO 1996-US13632W 19960821	
	BR 9612779	A	20001024	BR 1996-12779	19960821
				WO 1996-US2260 A 19960216	
				WO 1996-US13632W 19960821	

	US 6005008	A	19991221	US 1997-894291	19970815
				WO 1996-US2260 W	19960216
	US 6211373	B1	20010403	US 1998-111663	19980708
				US 1995-390260 B1	19950217
				WO 1996-US2260 W	19960216
				US 1996-641990 A3	19960320
				US 1996-701299 A3	19960821
	NO 9803737	A	19981014	NO 1998-3737	19980814
				US 1995-390260 A	19950217
				WO 1996-US2260 W	19960216
	US 6180675	B1	20010130	US 1999-240354	19990129
				US 1995-390260 B2	19950217
				WO 1996-US2260 A2	19960216
				US 1996-641990 A3	19960320

FAN 1998:123975

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9806262	A1	19980219	WO 1997-US14825	19970815
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			US 1996-23991P P	19960815
CA 2245927	AA	19970821	CA 1996-2245927	19960821
			US 1996-23991P P	19960815
EP 920253	A1	19990609	EP 1997-939515	19970815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
			US 1996-23991P P	19960815
			WO 1997-US14825W	19970815
JP 2001527519	T2	20011225	JP 1998-510117	19970815
			US 1996-23991P P	19960815
			WO 1997-US14825W	19970815

FAN 1998:479029

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5780483	A	19980714	US 1996-701299	19960821
			US 1995-390260 B2	19950217
			US 1996-641990 A2	19960320
US 5886044	A	19990323	US 1996-641990	19960320
			US 1995-390260 B2	19950217
US 6211373	B1	20010403	US 1998-111663	19980708
			US 1995-390260 B1	19950217
			WO 1996-US2260 W	19960216
			US 1996-641990 A3	19960320
			US 1996-701299 A3	19960821

FAN 2001:521916

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6262113	B1	20010717	US 1998-125279	19980814
			US 1996-641990 A2	19960320
			WO 1996-US13632W	19960821
US 5886044	A	19990323	US 1996-641990	19960320
			US 1995-390260 B2	19950217
WO 9729743	A1	19970821	WO 1996-US13632	19960821
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,				

IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

WO 1996-US2260 A 19960216
WO 1996-US2260 A219960216
US 2002128321 A1 20020912 US 2001-871076 20010531
WO 1996-US13632W 19960821
US 1998-125279 A319980814

OS MARPAT 130:267221

IT **182499-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylureas as IL-8 receptor antagonists)

RN 182499-00-9 CAPLUS

CN Glycine, N-[3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; X = O, S; R = OH; R1 = H, halo, NO2, etc.; Y = H, halo, CN, etc.; n = 1-3; m = 1-3], useful in the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8), such as psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, ARDS, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, restenosis, angiogenesis, glomerulonephritis, thrombosis, Alzheimer's disease, graft vs. host reaction, allograft rejection, etc., were prepared E.g., reaction of Me 4-amino-3-hydroxybenzoate with Ph isocyanate afforded 90% I [R = OH; R1 = 4-(MeOCO); Y = H; m = 1]. All exemplified compds. I showed IC50 from 45 to <1 μ/mL for IL-8 receptor inhibition. Compds. I were also found to be inhibitors of Gro-α binding at about the same level.

RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:479029 CAPLUS

DN 129:122458
TI Preparation of N,N'-diphenylurea derivatives as interleukin-8 receptor antagonists
IN Widdowson, Katherine Louisa; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Philip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corporation, USA
SO U.S., 50 pp., Cont.-in-part of U.S. Ser. No. 641,990.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5780483	A	19980714	US 1996-701299	19960821
				US 1995-390260 B219950217	
				US 1996-641990 A219960320	
	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B219950217	
	US 6211373	B1	20010403	US 1998-111663	19980708
				US 1995-390260 B119950217	
				WO 1996-US2260 W	19960216
				US 1996-641990 A319960320	
				US 1996-701299 A319960821	

PATENT FAMILY INFORMATION:
FAN 1996:643902

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9625157	A1	19960822	WO 1996-US2260	19960216
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-390260 A219950217	
	EP 809492	A1	19971203	EP 1996-906547	19960216
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
				US 1995-390260 A 19950217	
				WO 1996-US2260 W	19960216
	JP 11503110	T2	19990323	JP 1996-525199	19960216
				US 1995-390260 A 19950217	
				WO 1996-US2260 W	19960216
	CA 2432662	AA	19970821	CA 1996-2432662	19960821
				WO 1996-US2260 A	19960216
				CA 1996-2245927A319960821	
	WO 9729743	A1	19970821	WO 1996-US13632	19960821
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				WO 1996-US2260 A	19960216
				WO 1996-US2260 A219960216	
	AU 9669007	A1	19970902	AU 1996-69007	19960821
	AU 725456	B2	20001012		
				WO 1996-US2260 A	19960216
				WO 1996-US13632W	19960821
	EP 896531	A1	19990217	EP 1996-929723	19960821
	R: AT, ES, GR, LU, SE, MC, PT, IE, SI, LT, LV, FI				
				WO 1996-US2260 W	19960216

				WO 1996-US13632W 19960821
	CN 1215990	A	19990505	CN 1996-180245 19960821
				WO 1996-US2260 A 19960216
	JP 2000504722	T2	20000418	JP 1997-529318 19960821
				WO 1996-US2260 W 19960216
				WO 1996-US13632W 19960821
	NZ 316710	A	20000526	NZ 1996-316710 19960821
				WO 1996-US2260 A 19960216
				WO 1996-US13632W 19960821
	BR 9612779	A	20001024	BR 1996-12779 19960821
				WO 1996-US2260 A 19960216
				WO 1996-US13632W 19960821
	US 6005008	A	19991221	US 1997-894291 19970815
				WO 1996-US2260 W 19960216
	US 6211373	B1	20010403	US 1998-111663 19980708
				US 1995-390260 B119950217
				WO 1996-US2260 W 19960216
				US 1996-641990 A319960320
				US 1996-701299 A319960821
	NO 9803737	A	19981014	NO 1998-3737 19980814
				US 1995-390260 A 19950217
				WO 1996-US2260 W 19960216
	US 6180675	B1	20010130	US 1999-240354 19990129
				US 1995-390260 B219950217
				WO 1996-US2260 A219960216
				US 1996-641990 A319960320

FAN 1998:123975

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 9806262	A1	19980219	WO 1997-US14825 19970815
	W: JP, US			
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
				US 1996-23991P P 19960815
	CA 2245927	AA	19970821	CA 1996-2245927 19960821
				US 1996-23991P P 19960815
	EP 920253	A1	19990609	EP 1997-939515 19970815
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
				US 1996-23991P P 19960815
				WO 1997-US14825W 19970815
	JP 2001527519	T2	20011225	JP 1998-510117 19970815
				US 1996-23991P P 19960815
				WO 1997-US14825W 19970815

FAN 1999:205323

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 5886044	A	19990323	US 1996-641990 19960320
				US 1995-390260 B219950217
	US 5780483	A	19980714	US 1996-701299 19960821
				US 1995-390260 B219950217
				US 1996-641990 A219960320
	US 6211373	B1	20010403	US 1998-111663 19980708
				US 1995-390260 B119950217
				WO 1996-US2260 W 19960216
				US 1996-641990 A319960320
				US 1996-701299 A319960821
	US 6262113	B1	20010717	US 1998-125279 19980814

				US 1996-641990 A219960320
				WO 1996-US13632W 19960821
	US 6180675	B1	20010130	US 1999-240354 19990129
				US 1995-390260 B219950217
				WO 1996-US2260 A219960216
				US 1996-641990 A319960320

FAN 2001:521916

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6262113	B1	20010717	US 1998-125279	19980814
				US 1996-641990 A219960320	
				WO 1996-US13632W 19960821	
	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B219950217	
	WO 9729743	A1	19970821	WO 1996-US13632	19960821

W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

				WO 1996-US2260 A 19960216
				WO 1996-US2260 A219960216
	US 2002128321	A1	20020912	US 2001-871076 20010531
				WO 1996-US13632W 19960821
				US 1998-125279 A319980814

OS MARPAT 129:122458

IT **182499-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)

RN 182499-00-9 CAPLUS

CN Glycine, N-[3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; X = O, S; R = any functional moiety having an ionizable H and a pKa of ≤10 (sic); R1, Y = H, halo, NO2, cyano, (halo)alkyl, alkenyl, (halo)alkoxy, N3, HO, hydroxyalkyl, aryl, arylalkyl, aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, arylalkenyl, heteroarylalkenyl, (un)substituted NH2, CONH2, or SO3H, etc.; m, n = 1-3], which are useful for the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8) (no data), are prepared Thus, Me 4-amino-3-hydroxybenzoate was added to a solution of Ph isocyanate in PhMe and the resulting mixture was stirred at .apprx.80° for 24-48 h to give 90% N-[2-hydroxy-4-(methoxycarbonyl)phenyl]-N'-phenylurea.

RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:402427 CAPLUS
DN 129:81759
TI Preparation and formulation of benzodiazepine derivatives as gastrin and cholecystokinin antagonists
IN Shinozaki, Katsuo; Yoneta, Tomoyuki; Murata, Masakazu; Miura, Naoyoshi; Maeda, Kiyoto
PA Zeria Pharmaceutical Co., Ltd., Japan; Shinozaki, Katsuo;; Yoneta, Tomoyuki;; Murata Masakazu;; Miura, Naoyoshi;; Maeda, Kiyoto;
SO PCT Int. Appl., 432 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9825911	A1	19980618	WO 1997-JP4534	19971210
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1996-344498 A	19961210
				JP 1997-156132 A	19970530
	AU 9854100	A1	19980703	AU 1998-54100	19971210
	AU 721081	B2	20000622		
				JP 1996-344498 A	19961210
				JP 1997-156132 A	19970530
				WO 1997-JP4534 W	19971210
	EP 945445	A1	19990929	EP 1997-947872	19971210
	EP 945445	B1	20030903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				JP 1996-344498 A	19961210
				JP 1997-156132 A	19970530
				WO 1997-JP4534 W	19971210
	CN 1246850	A	20000308	CN 1997-181599	19971210
	CN 1130351	B	20031210		
				JP 1996-344498 A	19961210
				JP 1997-156132 A	19970530
	AT 248823	E	20030915	AT 1997-947872	19971210
				JP 1996-344498 A	19961210
				JP 1997-156132 A	19970530
				WO 1997-JP4534 W	19971210
	US 6239131	B1	20010529	US 1999-319249	19990608

JP 1996-344498 A 19961210
JP 1997-156132 A 19970530
WO 1997-JP4534 W 19971210

KR 2000057506 A 20000915 KR 1999-705193 19990610
JP 1996-344498 A 19961210
JP 1997-156132 A 19970530

OS MARPAT 129:81759

IT **209218-58-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzodiazepine derivs. as gastrin and cholecystokinin antagonists)

RN 209218-58-6 CAPLUS

CN Glycine, N-[3-[[[[5-(2,2-dimethyl-1-oxopropyl)-2,3,4,5-tetrahydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. I [R1 represents hydrogen, lower alkyl, lower alkoxy or halogeno; R2 and R3 may be the same or different and each represents hydrogen, alkenyl, alkyl, Ph, acyl, etc.; and R4 and R5 may be the same or different and each represents hydrogen, alkyl, carboxyl, etc.; Ar = aromatic heterocycle, etc.; n = 0 or 2] are prepared The compds. have an excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder. In an in vitro test for CCK-B receptor antagonism, the title compound (+)-II showed the Ki value of 1.16 nM. (+)-II at 1 mg/kg intraduodenally gave 81% inhibition of stomach acid secretion induced by pentagastrin 15 μg/kg/h in rats.

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:290093 CAPLUS
DN 126:264011
TI Preparation of meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
IN Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard John; Rico, Joseph Gerace; Rogers, Thomas Edward; Russell, Mark Andrew; et al.
PA G.D. Searle and Co., USA; Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard, John
SO PCT Int. Appl., 930 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9708145	A1	19970306	WO 1996-US13500	19960827
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
				US 1995-3277P	P 19950830
	CA 2230209	AA	19970306	CA 1996-2230209	19960827
				US 1995-3277P	P 19950830
	AU 9671039	A1	19970319	AU 1996-71039	19960827
	AU 702487	B2	19990225		
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	EP 850221	A1	19980701	EP 1996-932142	19960827
	EP 850221	B1	20010718		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	CN 1201454	A	19981209	CN 1996-197911	19960827
	CN 1085980	B	20020605		
				US 1995-3277P	P 19950830
	BR 9610422	A	19990713	BR 1996-10422	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	JP 11510814	T2	19990921	JP 1996-510397	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	IL 123164	A1	20010319	IL 1996-123164	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	AT 203234	E	20010815	AT 1996-932142	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	ES 2161373	T3	20011201	ES 1996-932142	19960827
				US 1995-3277P	P 19950830
	RU 2196769	C2	20030120	RU 1998-105408	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	RO 118290	B1	20030430	RO 2001-1069	19960827
				US 1995-3277P	P 19950830
	RO 118289	B1	20030430	RO 1998-500	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	PL 186370	B1	20031231	PL 1996-325312	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	ZA 9607379	A	19980330	ZA 1996-7379	19960830
				US 1995-3277P	P 19950830
	NO 9800817	A	19980424	NO 1998-817	19980226
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	HK 1021532	A1	20020208	HK 1998-114666	19981228
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827

	GR 3036751	T3	20011231	GR 2001-401608 20010928 US 1995-3277P P 19950830 WO 1996-US13500W 19960827

PATENT FAMILY INFORMATION:

FAN 2000:31349

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6013651	A	20000111	US 1998-34758	19980304
				US 1995-3277P P	19950830
				US 1996-713555 A2	19960827
	US 6028223	A	20000222	US 1996-713555	19960827
				US 1995-3277P P	19950830
	TW 458956	B	20011011	TW 1996-85115118	19961206
				US 1996-713555 A	19960827
	US 6100423	A	20000808	US 1999-261822	19990303
				US 1995-3277P P	19950830
				US 1996-713555 A2	19960827
				US 1998-34758 A2	19980304

FAN 2000:547503

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6100423	A	20000808	US 1999-261822	19990303
				US 1995-3277P P	19950830
				US 1996-713555 A2	19960827
				US 1998-34758 A2	19980304
	US 6028223	A	20000222	US 1996-713555	19960827
				US 1995-3277P P	19950830
	TW 458956	B	20011011	TW 1996-85115118	19961206
				US 1996-713555 A	19960827
	US 6013651	A	20000111	US 1998-34758	19980304
				US 1995-3277P P	19950830
				US 1996-713555 A2	19960827

OS MARPAT 126:264011

IT **188812-13-7P 188812-32-0P 188812-36-4P**
188812-75-1P 188813-15-2P 188813-65-2P
188813-67-4P 188813-70-9P 188813-72-1P
188813-74-3P 188813-98-1P 188814-01-9P
188814-42-8P 188814-74-6P 188814-82-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188812-13-7 CAPLUS

CN Glycine, N-[3-[(aminoiminomethyl)amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188812-32-0 CAPLUS
CN Glycine, N-[3-[(aminocarbonyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188812-36-4 CAPLUS
CN Glycine, N-[3-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188812-75-1 CAPLUS
CN Glycine, N-[3-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-15-2 CAPLUS
CN Glycine, N-[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-65-2 CAPLUS
CN Glycine, N-[3-[[[(4-pyridinylmethyl)amino]carbonyl]amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188813-67-4 CAPLUS
CN Glycine, N-[3-[[[(2-pyridinylmethyl)amino]carbonyl]amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188813-70-9 CAPLUS
CN Glycine, N-[3-[[[(1-phenylethyl)amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-72-1 CAPLUS
CN Glycine, N-[3-[[[(1H-benzimidazol-2-ylmethyl)amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-74-3 CAPLUS
CN Glycine, N-[3-[[[[(3,5-dichlorophenyl)methyl]amino]carbonyl]amino]benzoyl]-

(9CI) (CA INDEX NAME)



RN 188813-98-1 CAPLUS
CN Glycine, N-[3-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188814-01-9 CAPLUS
CN Glycine, N-[3-[(4-phenyl-1H-imidazol-2-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188814-42-8 CAPLUS
CN Glycine, N-[3-[(1,4,5,6-tetrahydro-5,5-dimethyl-2-pyrimidinyl)amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188814-74-6 CAPLUS
CN 1(4H)-Pyrimidinecarboxylic acid, 2-[[3-[[(carboxymethyl)amino]carbonyl]phenyl]amino]-5,6-dihydro-, 1-phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188814-73-5
CMF C20 H20 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 188814-82-6 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[[3-[[(carboxymethyl)amino]carbonyl]phenyl]amino]-4,5-dihydro-, 1-ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



I



II

AB The title compds. I [A = (un)substituted ureido, guanidino, etc. (generic structures given); Z1 = H, alkyl, OH, alkoxy, halo, (di)(alkyl)amino, aryl, etc.; V = NR6; R6 = H, alkyl, etc.; or YR6 forms a 4- to 12-membered mono-N-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl; or YZ or Y3Z3 form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = XR3; X = O, S, NH, etc.; R3 = H, alkyl, etc.; R1 = H, alkyl, alkenyl, etc.; R11 = H, alkyl, aralkyl, etc.] are prepared For example, m-nitrohippuric acid was subjected to a sequence of (1) amidation with Et 3-amino-3-(3-pyridyl)propanoate-2HCl; (2) hydrogenation of the nitro group; (3) reaction of the formed amine with benzyl isocyanate; and (4) alkaline saponification of the ester, to give title compound II, isolated as the CF3CO2H or HCl salt. In an in vitro assay for antagonism of human vitronectin receptor (αVβ3), the title compound II.HCl bound with an IC50 of 0.86 nM.

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:643902 CAPLUS
DN 125:275430
TI Preparation of N,N'-diphenylurea derivatives as interleukin-8 receptor antagonists
IN Widdowson, Katherine Louisa; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Rutledge, Melvin Clarence, Jr.; Hertzberg, Robert Philip
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9625157	A1	19960822	WO 1996-US2260	19960216
	W: JP, US				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 1995-390260 A219950217
EP 809492 A1 19971203 EP 1996-906547 19960216
R: BE, CH, DE, DK, FR, GB, IT, LI, NL
US 1995-390260 A 19950217
WO 1996-US2260 W 19960216
JP 11503110 T2 19990323 JP 1996-525199 19960216
US 1995-390260 A 19950217
WO 1996-US2260 W 19960216
CA 2432662 AA 19970821 CA 1996-2432662 19960821
WO 1996-US2260 A 19960216
CA 1996-2245927A319960821
WO 9729743 A1 19970821 WO 1996-US13632 19960821
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
WO 1996-US2260 A 19960216
WO 1996-US2260 A219960216
AU 9669007 A1 19970902 AU 1996-69007 19960821
AU 725456 B2 20001012
WO 1996-US2260 A 19960216
WO 1996-US13632W 19960821
EP 896531 A1 19990217 EP 1996-929723 19960821
R: AT, ES, GR, LU, SE, MC, PT, IE, SI, LT, LV, FI
WO 1996-US2260 W 19960216
WO 1996-US13632W 19960821
CN 1215990 A 19990505 CN 1996-180245 19960821
WO 1996-US2260 A 19960216
JP 2000504722 T2 20000418 JP 1997-529318 19960821
WO 1996-US2260 W 19960216
WO 1996-US13632W 19960821
NZ 316710 A 20000526 NZ 1996-316710 19960821
WO 1996-US2260 A 19960216
WO 1996-US13632W 19960821
BR 9612779 A 20001024 BR 1996-12779 19960821
WO 1996-US2260 A 19960216
WO 1996-US13632W 19960821
US 6005008 A 19991221 US 1997-894291 19970815
WO 1996-US2260 W 19960216
US 6211373 B1 20010403 US 1998-111663 19980708
US 1995-390260 B119950217
WO 1996-US2260 W 19960216
US 1996-641990 A319960320
US 1996-701299 A319960821
NO 9803737 A 19981014 NO 1998-3737 19980814
US 1995-390260 A 19950217
WO 1996-US2260 W 19960216
US 6180675 B1 20010130 US 1999-240354 19990129
US 1995-390260 B219950217
WO 1996-US2260 A219960216
US 1996-641990 A319960320

PATENT FAMILY INFORMATION:
FAN 1998:123975
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9806262	A1	19980219	WO 1997-US14825	19970815
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1996-23991P P	19960815
	CA 2245927	AA	19970821	CA 1996-2245927	19960821
				US 1996-23991P P	19960815
	EP 920253	A1	19990609	EP 1997-939515	19970815
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1996-23991P P	19960815
				WO 1997-US14825W	19970815
	JP 2001527519	T2	20011225	JP 1998-510117	19970815
				US 1996-23991P P	19960815
				WO 1997-US14825W	19970815

FAN 1998:479029

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5780483	A	19980714	US 1996-701299	19960821
				US 1995-390260 B2	19950217
				US 1996-641990 A2	19960320
	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B2	19950217
	US 6211373	B1	20010403	US 1998-111663	19980708
				US 1995-390260 B1	19950217
				WO 1996-US2260 W	19960216
				US 1996-641990 A3	19960320
				US 1996-701299 A3	19960821

FAN 1999:205323

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B2	19950217
	US 5780483	A	19980714	US 1996-701299	19960821
				US 1995-390260 B2	19950217
				US 1996-641990 A2	19960320
	US 6211373	B1	20010403	US 1998-111663	19980708
				US 1995-390260 B1	19950217
				WO 1996-US2260 W	19960216
				US 1996-641990 A3	19960320
				US 1996-701299 A3	19960821
	US 6262113	B1	20010717	US 1998-125279	19980814
				US 1996-641990 A2	19960320
				WO 1996-US13632W	19960821
	US 6180675	B1	20010130	US 1999-240354	19990129
				US 1995-390260 B2	19950217
				WO 1996-US2260 A2	19960216
				US 1996-641990 A3	19960320

FAN 2001:521916

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6262113	B1	20010717	US 1998-125279	19980814
				US 1996-641990 A2	19960320
				WO 1996-US13632W	19960821
	US 5886044	A	19990323	US 1996-641990	19960320
				US 1995-390260 B2	19950217
	WO 9729743	A1	19970821	WO 1996-US13632	19960821

W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

WO 1996-US2260 A 19960216
WO 1996-US2260 A219960216
US 2002128321 A1 20020912 US 2001-871076 20010531
WO 1996-US13632W 19960821
US 1998-125279 A319980814

OS MARPAT 125:275430

IT **182499-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)

RN 182499-00-9 CAPLUS

CN Glycine, N-[3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; X = O, S; R = any functional moiety having an ionizable H and a pKa of ≤10; R1, Y = H, halo, NO2, cyano, C1-10 (halo)alkyl, C2-10 alkenyl, C1-10 (halo)alkoxy, N3, HO, C1-4 hydroxyalkyl, aryl, aryl-C1-4 alkyl, aryloxy, aryl-C1-4 alkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, heterocyclyl-C1-4 alkoxy, aryl-C2-10 alkenyl, heteroaryl-C2-10 alkenyl, (un)substituted NH2, carbamoyl, or SO3H, etc.; m, n = 1-3], which are useful for the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8) (no data), are prepared The chemokine-mediated disease is selected from psoriasis or atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, thrombosis, Alzheimer's disease, graft vs. host reaction, and allograft rejections. Thus, 1.19

mmol Me 4-amino-3-hydroxybenzoate was added to a solution of 1.19 mmol Ph isocyanate in toluene and the resulting mixture was stirred at .apprx.80° for 24-48 h to give 90% N-[2-hydroxy-4-(methoxycarbonyl)phenyl]-N'-phenylurea.

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:365469 CAPLUS
DN 125:33692
TI Preparation of oxobenzodiazepinylureas as CCK and gastrin antagonists
IN Sato, Yoshinari; Sakane, Kazuo; Tabuchi, Seiichiro; Mitsui, Hitoshi; Katsumi, Ikuyo; Satoh, Yuichi
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Nippon Shokubai Co., Ltd.
SO PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604254	A2	19960215	WO 1995-JP1497	19950727
	WO 9604254	A3	19960620		
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1994-15311	19940729
				GB 1995-1726	19950130
	CA 2196062	AA	19960215	CA 1995-2196062	19950727
				GB 1994-15311	19940729
				GB 1995-1726	19950130
	EP 804425	A2	19971105	EP 1995-926512	19950727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
				GB 1994-15311	19940729
				GB 1995-1726	19950130
				WO 1995-JP1497	19950727
	JP 10504545	T2	19980506	JP 1995-506388	19950727
				GB 1994-15311	19940729
				GB 1995-1726	19950130
				WO 1995-JP1497	19950727
	US 5763437	A	19980609	US 1997-776196	19970129
				GB 1994-15311	19940729
				GB 1995-1726	19950130
				WO 1995-JP1497	19950727

OS MARPAT 125:33692
IT **177783-65-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxobenzodiazepinylureas as CCK and gastrin antagonists)
RN 177783-65-2 CAPLUS
CN Glycine, N-[3-[[[[1-[2-(3-azabicyclo[3.2.2]non-3-yl)-2-oxoethyl]-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; R = C(:Y)ZR2; R1 = (un)substituted aryl, (un)substituted cycloalkyl; R2 = (un)substituted aryl, (un)substituted cycloalkyl, etc.; R5 = Z1R3; R3 = tetrahydrofuryl, thienyl, quinolyl, XR4, etc.; R4 = thiomorpholinyl, pyridyl, cyclohydrocarbyl, etc.; X = CO, CO2, CONH, etc.; Y = O or S; Z = bond, (alkyl)imino; Z1 = alkylene] were prepared Thus, I (R1 = C6H4F-2)(II; R = CO2CH2Ph, R5 = CH2CO2H)(preparation given) was amidated by 3-azabicyclo[3.2.2]nonane and the deprotected product N-acylated by 3-MeC6H4NCO to give II [R = CONHC6H4Me-3, R5 = CH2COR4, R4 = 3-azabicyclo[3.2.2]nonan-3-yl] which gave 98.0% inhibition of CCK-8 binding at guinea pig cerebral cortex membrane preparation at 10-8M in vitro.

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:667081 CAPLUS
DN 123:55917
TI Antithrombogenic piperazine derivatives.
IN Gante, Joachim; Raddatz, Peter; Juraszyk, Horst; Bernotat-Danielowski, Sabine; Melzer, Guido
PA Merck Patent G.m.b.H., Germany
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 608759	A2	19940803	EP 1994-100709	19940119
	EP 608759	A3	19941005		
	EP 608759	B1	20010822		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				DE 1993-4302485A	19930129
	DE 4302485	A1	19940804	DE 1993-4302485	19930129
	JP 06271549	A2	19940927	JP 1994-3451	19940118
				DE 1993-4302485A	19930129
	AT 204570	E	20010915	AT 1994-100709	19940119
				DE 1993-4302485A	19930129
	ES 2162825	T3	20020116	ES 1994-100709	19940119
				DE 1993-4302485A	19930129
	PT 608759	T	20020228	PT 1994-94100709	19940119
				DE 1993-4302485A	19930129
	SK 281842	B6	20010806	SK 1994-68	19940120
				DE 1993-4302485A	19930129
	AU 9454702	A1	19940804	AU 1994-54702	19940125
	AU 670649	B2	19960725		
				DE 1993-4302485A	19930129
	CN 1099759	A	19950308	CN 1994-101127	19940125
	CN 1056141	B	20000906		
				DE 1993-4302485A	19930129
	CZ 288122	B6	20010411	CZ 1994-163	19940125
				DE 1993-4302485A	19930129
	CA 2114361	AA	19940730	CA 1994-2114361	19940127
				DE 1993-4302485A	19930129
	NO 9400308	A	19940801	NO 1994-308	19940128
				DE 1993-4302485A	19930129
	ZA 9400615	A	19940913	ZA 1994-615	19940128
				DE 1993-4302485A	19930129
	HU 70042	A2	19950928	HU 1994-249	19940128
				DE 1993-4302485A	19930129
	PL 172716	B1	19971128	PL 1994-302069	19940128
				DE 1993-4302485A	19930129
	RU 2154639	C2	20000820	RU 1994-2323	19940128
				DE 1993-4302485A	19930129
	US 5908843	A	19990601	US 1994-189385	19940131
				DE 1993-4302485A	19930129
	GR 3036838	T3	20020131	GR 2001-401700	20011009
				DE 1993-4302485A	19930129

OS MARPAT 123:55917

IT **164785-10-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antithrombogenic piperazines)

RN 164785-10-8 CAPLUS

CN Glycine, N-[3-[[imino[[(phenylmethoxy)carbonyl]amino]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



IT **164784-19-4P 164784-20-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antithrombogenic piperazines)
RN 164784-19-4 CAPLUS
CN Glycine, N-[3-[(1-piperazinylcarbonyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 164784-20-7 CAPLUS
CN Glycine, N-[3-[[[4-(aminoiminomethyl)-1-piperazinyl]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



GI





AB The title compds. Y(CmH2mCHR1)nCO(NHCHR2CO)rZ [I; R1, R2 = (un)substituted PhCH2, etc.; Y = Q1, 4-R5C6H4; Z = Q1, Q2, etc.; R3 = H, H2NC(:NH)NH; R4, R6 = H2, :O; R7 = R1; R8 = OH, NHOH, etc.; m = 0-4; n, r = 0, 1; p = 0-2], useful as antithrombotics (no data), antineoplastic agents (no data), antiatherosclerotics (no data), etc., are prepared and I-containing formulations
presented. Thus, 3-[4-(4-guanidinobenzoyl)-2-oxo-1-piperazinyl]propionic acid, m.p. 110° (decomposition), was prepared

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:680467 CAPLUS
DN 121:280467
TI Preparation of antibiotic carbapenem compounds
IN Betts, Michael John; Davies, Gareth Morse; Jung, Frederic Henri
PA Zeneca Ltd., UK; Zeneca Pharma S.A.
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 590885	A1	19940406	EP 1993-307551	19930923
EP 590885	B1	20000315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			EP 1992-402648 A	19920928
CA 2106141	AA	19940329	CA 1993-2106141	19930914
			EP 1992-402648 A	19920928
US 5527791	A	19960618	US 1993-123998	19930921
			EP 1992-402648 A	19920928
AT 190615	E	20000415	AT 1993-307551	19930923
			EP 1992-402648 A	19920928
ES 2144446	T3	20000616	ES 1993-307551	19930923
			EP 1992-402648 A	19920928
JP 06211860	A2	19940802	JP 1993-241519	19930928
			EP 1992-402648 A	19920928

OS MARPAT 121:280467
IT **158742-92-8P**
RL: PREP (Preparation)
(prepare of, as antibiotic)
RN 158742-92-8 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[[3-[[(carboxymethyl)amino]carbonyl]phenyl]amino]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

GI



I

AB Title compds. I (A = (substituted) Ph or thienyl; R1 = MeCH(OH), MeCHF, HOCH2; R2 = H, C1-4 alkyl; R3, R4 = H, halo, NC, C1-4 alkyl, O2N, HO, HO2C, C1-4 alkoxy, F3C, etc.;X = c1-6 alkanediyl interrupted by O, S(O)x wherein x = 0-2, R5NCO wherein R5 = H, C1-4 alkyl) or a salt or in vivo hydrolysable ester , are prepared To allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(3(E-allyloxycarbonyl-1-ethenyl)phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (preparation given) and Maldrum's acid in DMF and THF was added (Ph3P)4Pd followed by Na 2-ethylhexanoate to give the title compound (1R,5S,6S,8R,2'S,4'S)-2-(2-(3(E-2-carboxy-1-ethenyl)phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid, di-Na salt (II). In vitro against S. aureus the min. inhibitory concentration of II was 0.13 μg/mL ws. 2.0 μg/mL of ceftriaxone. Pharmaceutical formulations comprising I are given.

L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245179 CAPLUS
DN 120:245179
TI Preparation of benzodiazepine derivatives as cholecystokinin B and gastrin receptor antagonists
IN Satoh, Masato; Okamoto, Yoshinori; Koshio, Hiroyuki; Nishida, Akito; Miyata, Keiji; Ohta, Mitsuaki; Ryder, Hamish; Kendrick, David A.; Semple, Graeme; Szelke, Michael
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Ferring B.V.
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9400438	A1	19940106	WO 1993-JP844	19930622
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			JP 1992-189826	19920624
AU 9343570	A1	19940124	AU 1993-43570	19930622
AU 670597	B2	19960725		
			JP 1992-189826	19920624
			WO 1993-JP844	19930622
EP 647632	A1	19950412	EP 1993-913562	19930622

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

			JP 1992-189826	19920624
			WO 1993-JP844	19930622
HU 68208	A2	19950628	HU 1994-3785	19930622
			JP 1992-189826	19920624
JP 2726158	B2	19980311	JP 1993-502202	19930622
			JP 1992-189826	19920624
FI 9405989	A	19941221	FI 1994-5989	19941221
			JP 1992-189826	19920624
			WO 1993-JP844	19930622
NO 9405033	A	19950224	NO 1994-5033	19941223
			JP 1992-189826	19920624
			WO 1993-JP844	19930622

OS MARPAT 120:245179

IT **154063-73-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin B and gastrin receptor antagonist)

RN 154063-73-7 CAPLUS

CN Glycine, N-[3-[[[[2,3-dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



GI



I



II



III

AB The title compds. I [R1 = H, alkyl, OH; R2 = Ph having one or more substituents, pyridyl, etc. (further details on substituents of said Ph are given); R3 = Ph, pyridiyl; a proviso is given] were prepared I inhibit gastric juice secretion. Treatment of benzodiazepine II with 40% HBr in AcOH, followed by reaction with m-tolyl isocyanate, gave benzodiazepine III. The title compds. in vitro exhibited an IC50 of 0.16 to 2.14 mM against cholecystokinin B binding. Formulations containing I are given.

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1985:103657 CAPLUS
DN 102:103657
TI Photothermographic color imaging process
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59174835	A2	19841003	JP 1983-48753	19830325
	JP 02051495	B4	19901107		
	US 5064742	A	19911112	US 1990-504068	19900329
				JP 1983-48753	19830325
				US 1984-592203	19840322

IT **94973-29-2**
RL: USES (Uses)
(color diffusion-transfer photothermog. coupler)
RN 94973-29-2 CAPLUS
CN Glycine, N-[3-[[4-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]thio]-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]amino]-4-

chlorobenzoyl]- (9CI) (CA INDEX NAME)



GI



AB A photothermog. process is claimed in which a photosensitive sheet containing Ag halide, a hydrophilic binder, a reducing agent (for Ag halide), and a diffusion-resistant 2-equivalent coupler which forms a diffusible hydrophilic dye is imagewise exposed and developed to form diffusible dye images, and the dye images are transferred onto a dye-mordanting layer at an elevated temperature in the presence of a hydrophilic low m.p. Thus, a polyester film support was coated with a composition containing gelatin and Me acrylate-trimethyl(vinylbenzyl)ammonium chloride copolymer and coated with a high temperature solvent composition containing urea, poly(vinyl alc.), p-C9H19C6H4O(CH2CH2O)8H, and Na dodecylbenzenesulfonate to give a receptor sheet. Sep., another film support was coated with a composition containing Ag(Br,Cl) emulsion, I, guanidine trichloroacetate, 2,6-dichloro-4-aminophenol and p-C9H19C6H4O(CH2CH2O)8H to give a photothermog. film. The film was imagewise exposed, heated at 130°, then contacted with the receptor sheet and heated at 120° to form clear magenta dye images on the receptor.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:33:40 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 10:33:51 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2          41 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 10:34:24 ON 28 APR 2004
L3          71 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 10:37:55 ON 28 APR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 10:38:02 ON 28 APR 2004
L4          41 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 10:38:03 ON 28 APR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:38:08 ON 28 APR 2004
L6          15 S L2
L7          71 S L3

=> s l2 and l3
EXPRESSION CONTAINS ANSWER SETS CREATED IN MORE THAN ONE
ADDITIONAL FILE
The query entered contains answer sets from two different
files, other than the current file, as search terms.
File crossover can only be done from one file to another.

=> s l6 and l7
L8          2 L6 AND L7

=> d l8 fbib hitstr abs total

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2000:335391  CAPLUS
DN   132:347569
TI   Preparation gastrin and cholecystokinin receptor ligands
IN   Kalindjian, Sarkis Barret; Buck, Ildiko Maria; Linney, Ian Duncan; Wright,
     Paul Trevor; McDonald, Iain Mair; Steel, Katherine Isobel Mary; Hull,
     Robert Antony David; Roberts, Sonia Patricia; Gaffen, John David; Vinter,
     Jeremy Gilbert; Walker, Martin Keith; Black, James Whyte; Watt, Gillian
     Fairfull; Harper, Elaine Anne; Shankley, Nigel Paul; Tozer, Matthew John;
     Dunstone, David John; Pether, Michael John; Lilley, Elliot James; Sykes,
     David Andrew; Low, Caroline Minli Rachel; Griffin, Eric Peter; Wright,
     Laurence
PA   James Black Foundation Limited, UK
SO   PCT Int. Appl., 210 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.   DATE
     ----------------  ----  --------      ----------------  --------
PI   WO 2000027823      A1   20000518      WO 1999-GB3733    19991109
```

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:45:15 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:45:54 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10717238.4

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH
G2 O,S,NH
G3 NH,NH2,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

```
FULL SEARCH INITIATED 10:46:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    4137 TO ITERATE

100.0% PROCESSED    4137 ITERATIONS                          16 ANSWERS
SEARCH TIME: 00.00.01

L2            16 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.84     156.05

FILE 'MARPAT' ENTERED AT 10:46:58 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6709645 23 MAR 2004
DE   10335606 11 MAR 2004
EP    1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 10:47:03 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -  34119 TO ITERATE

 15.2% PROCESSED    5180 ITERATIONS                           3 ANSWERS

 28.0% PROCESSED    9558 ITERATIONS  (     1 INCOMPLETE)      4 ANSWERS

 47.4% PROCESSED   16184 ITERATIONS  (     2 INCOMPLETE)      7 ANSWERS

 73.0% PROCESSED   24912 ITERATIONS  (     2 INCOMPLETE)     10 ANSWERS

 81.1% PROCESSED   27671 ITERATIONS  (     2 INCOMPLETE)     11 ANSWERS

 84.3% PROCESSED   28770 ITERATIONS  (     2 INCOMPLETE)     11 ANSWERS

 89.8% PROCESSED   30649 ITERATIONS  (     2 INCOMPLETE)     12 ANSWERS

 94.4% PROCESSED   32208 ITERATIONS  (     3 INCOMPLETE)     13 ANSWERS

 97.7% PROCESSED   33326 ITERATIONS  (     3 INCOMPLETE)     14 ANSWERS

 99.7% PROCESSED   34026 ITERATIONS  (     3 INCOMPLETE)     14 ANSWERS

100.0% PROCESSED   34119 ITERATIONS  (     3 INCOMPLETE)     14 ANSWERS
SEARCH TIME: 00.02.55
```

L3 14 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	111.10	267.15

FILE 'CAOLD' ENTERED AT 10:50:04 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:50:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4137 TO ITERATE

100.0% PROCESSED 4137 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

L4 16 SEA SSS FUL L1

L5 0 L4

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	423.41

FILE 'CAPLUS' ENTERED AT 10:50:17 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:45:15 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 10:45:54 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 16 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:46:58 ON 28 APR 2004
L3 14 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:50:04 ON 28 APR 2004
S L1

FILE 'REGISTRY' ENTERED AT 10:50:12 ON 28 APR 2004
L4 16 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:50:13 ON 28 APR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:50:17 ON 28 APR 2004

=> s l2
L6 8 L2

=> s l3
L7 14 L3

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256040 CAPLUS
DN 136:279325
TI Preparation and use of amido-lactone integrin antagonists
IN Ruminiski, Peter; Penning, Thomas D.; Jiang, Lan; Balekudru, Devadas; Rogers, Thomas; Yuan, Chester; Vancamp, Jennifer
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026227	A1	20020404	WO 2001-US30194	20010927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2000-235617PP	20000927
				US 2000-241633PP	20001010
	US 2002045645	A1	20020418	US 2001-963926	20010926
	US 6720327	B2	20040413		
				US 2000-235617PP	20000927
				US 2000-241633PP	20001019
	EP 1320363	A1	20030625	EP 2001-975450	20010927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-235617PP	20000927
				US 2000-241633PP	20001010
				WO 2001-US30194W	20010927
	US 2004019206	A1	20040129	US 2003-381831	20030327
				WO 2001-US30194W	20010927

OS MARPAT 136:279325
IT **406703-74-0 406703-76-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation and use of amido-lactone integrin antagonists)
RN 406703-74-0 CAPLUS
CN Glycine, N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 406703-76-2 CAPLUS
CN Glycine, N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S: p, q = 0-3; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give II isolated as the TFA salt. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5

integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:672798 CAPLUS
DN 131:299691
TI Preparation of heterocyclic glycyl β-alanine derivatives as vitronectin antagonists
IN Chandrakumar, Nizal Samuel; Desai, Bipinchandra Nanubhai; Devadas, Balekudru; Huff, Renee; Khanna, Ish K.; Rao, Shashidhar N.; Rico, Joseph G.; Rogers, Thomas E.; Ruminski, Peter G.; Russell, Mark Andrew; Yu, Yi; Gasiecki, Alan Frank; Malecha, James W.; Miyashiro, Julie M.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952896	A1	19991021	WO 1999-US4297	19990409
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1998-81394P P	19980410
	US 6689754	B1	20040210	US 1999-289140	19990408
				US 1998-81394P P	19980410
	CA 2326665	AA	19991021	CA 1999-2326665	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	AU 9934499	A1	19991101	AU 1999-34499	19990409
	AU 765294	B2	20030911		
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	EP 1070060	A1	20010124	EP 1999-916119	19990409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	BR 9910119	A	20011009	BR 1999-10119	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	JP 2002511462	T2	20020416	JP 2000-543454	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	RU 2215746	C2	20031110	RU 2000-128033	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409
	NZ 507292	A	20031219	NZ 1999-507292	19990409
				US 1998-81394P P	19980410
				WO 1999-US4297 W	19990409

NO 2000005084 A 20001127 NO 2000-5084 20001009
US 1998-81394P P 19980410
WO 1999-US4297 W 19990409

OS MARPAT 131:299691

IT **247101-76-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic glycyl β-alanine derivs. as vitronectin antagonists)

RN 247101-76-4 CAPLUS

CN Glycine, N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



AB Tile compds. A(CY3Z3)t-Het-CO-V-(CYZ)n-CONR11CHR1(CH2)pCOR [Het = (un)substituted 5-8 membered monocyclic heterocyclic ring containing 1-4 heteroatoms selected from O, N, or S, optionally unsatd. and linked to (CY3Z3)t and CO at the 1- and 3-positions; A = NR5C(:Y1)NR7R8, NR5C(:NR7)Y2, or N:C(NR2R5)(NR7R8), where Y1 = NR2, O, S; R2, R7, R8 = H, alkyl, aryl, amino, etc. or R2 and R8 taken together form an (un)substituted dinitrogen heterocycle; R5 = H, alkyl, alkenyl, alkynyl, benzyl, phenethyl; and Y2 = alkyl, cycloalkyl, bicycloalkyl, aryl, etc.; V = NR6, where R6 = H, alkyl, cycloalkyl, aralkyl, aryl, monocyclic heterocyclyl or R6 together with Y forms a mono-nitrogen-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl or Y and Z together or Y3 and Z3 together form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = X-R3, where X = O, S, or NR4 and R3 and R4 = H, alkyl, sugars, steroids, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.] or their pharmaceutically acceptable salts were prepared as vitronectin antagonists. Thus, 5-[(aminoiminomethyl)amino]-N-[2-[[2-carboxy-1-(3-bromo-5-chloro-2-hydroxyphenyl)ethyl]amino]-2-oxoethyl]-3-pyridinecarboxamide bis(trifluoroacetate) was prepared and showed IC50 = 1.58 nM for inhibition of human vitronectin receptor (αvβ3).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:290093 CAPLUS

DN 126:264011

TI Preparation of meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists

IN Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard John; Rico, Joseph Gerace; Rogers, Thomas Edward; Russell, Mark Andrew; et al.

PA G.D. Searle and Co., USA; Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard,

John
SO PCT Int. Appl., 930 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9708145	A1	19970306	WO 1996-US13500	19960827
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
				US 1995-3277P	P 19950830
	CA 2230209	AA	19970306	CA 1996-2230209	19960827
				US 1995-3277P	P 19950830
	AU 9671039	A1	19970319	AU 1996-71039	19960827
	AU 702487	B2	19990225		
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	EP 850221	A1	19980701	EP 1996-932142	19960827
	EP 850221	B1	20010718		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	CN 1201454	A	19981209	CN 1996-197911	19960827
	CN 1085980	B	20020605		
				US 1995-3277P	P 19950830
	BR 9610422	A	19990713	BR 1996-10422	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	JP 11510814	T2	19990921	JP 1996-510397	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	IL 123164	A1	20010319	IL 1996-123164	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	AT 203234	E	20010815	AT 1996-932142	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	ES 2161373	T3	20011201	ES 1996-932142	19960827
				US 1995-3277P	P 19950830
	RU 2196769	C2	20030120	RU 1998-105408	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	RO 118290	B1	20030430	RO 2001-1069	19960827
				US 1995-3277P	P 19950830
	RO 118289	B1	20030430	RO 1998-500	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	PL 186370	B1	20031231	PL 1996-325312	19960827
				US 1995-3277P	P 19950830
				WO 1996-US13500W	19960827
	ZA 9607379	A	19980330	ZA 1996-7379	19960830
				US 1995-3277P	P 19950830

	NO 9800817	A	19980424	NO 1998-817 19980226
				US 1995-3277P P 19950830
				WO 1996-US13500W 19960827
	HK 1021532	A1	20020208	HK 1998-114666 19981228
				US 1995-3277P P 19950830
				WO 1996-US13500W 19960827
	GR 3036751	T3	20011231	GR 2001-401608 20010928
				US 1995-3277P P 19950830
				WO 1996-US13500W 19960827

PATENT FAMILY INFORMATION:

FAN 2000:31349

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 6013651	A	20000111	US 1998-34758 19980304
				US 1995-3277P P 19950830
				US 1996-713555 A219960827
	US 6028223	A	20000222	US 1996-713555 19960827
				US 1995-3277P P 19950830
	TW 458956	B	20011011	TW 1996-85115118 19961206
				US 1996-713555 A 19960827
	US 6100423	A	20000808	US 1999-261822 19990303
				US 1995-3277P P 19950830
				US 1996-713555 A219960827
				US 1998-34758 A219980304

FAN 2000:547503

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 6100423	A	20000808	US 1999-261822 19990303
				US 1995-3277P P 19950830
				US 1996-713555 A219960827
				US 1998-34758 A219980304
	US 6028223	A	20000222	US 1996-713555 19960827
				US 1995-3277P P 19950830
	TW 458956	B	20011011	TW 1996-85115118 19961206
				US 1996-713555 A 19960827
	US 6013651	A	20000111	US 1998-34758 19980304
				US 1995-3277P P 19950830
				US 1996-713555 A219960827

OS MARPAT 126:264011

IT **188812-75-1P 188813-15-2P 188813-98-1P 188814-01-9P 188814-42-8P 188814-74-6P 188814-82-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188812-75-1 CAPLUS

CN Glycine, N-[3-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-15-2 CAPLUS
CN Glycine, N-[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188813-98-1 CAPLUS
CN Glycine, N-[3-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188814-01-9 CAPLUS
CN Glycine, N-[3-[(4-phenyl-1H-imidazol-2-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 188814-42-8 CAPLUS
CN Glycine, N-[3-[(1,4,5,6-tetrahydro-5,5-dimethyl-2-pyrimidinyl)amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188814-74-6 CAPLUS
CN 1(4H)-Pyrimidinecarboxylic acid, 2-[[3-[[(carboxymethyl)amino]carbonyl]phenyl]amino]-5,6-dihydro-, 1-phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188814-73-5
CMF C20 H20 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 188814-82-6 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[[3-[[(carboxymethyl)amino]carbonyl]phenyl]amino]-4,5-dihydro-, 1-ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



I



II

AB The title compds. I [A = (un)substituted ureido, guanidino, etc. (generic structures given); Z1 = H, alkyl, OH, alkoxy, halo, (di)(alkyl)amino, aryl, etc.; V = NR6; R6 = H, alkyl, etc.; or YR6 forms a 4- to 12-membered mono-N-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl; or YZ or Y3Z3 form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = XR3; X = O, S, NH, etc.; R3 = H, alkyl, etc.; R1 = H, alkyl, alkenyl, etc.; R11 = H, alkyl, aralkyl, etc.] are prepared For example, m-nitrohippuric acid was subjected to a sequence of (1) amidation with Et 3-amino-3-(3-pyridyl)propanoate-2HCl; (2) hydrogenation of the nitro group; (3) reaction of the formed amine with benzyl isocyanate; and (4) alkaline saponification of the ester, to give title compound II, isolated as the CF3CO2H or HCl salt. In an in vitro assay for antagonism of human vitronectin receptor ($\alpha V\beta 3$), the title compound II.HCl bound with an IC50 of 0.86 nM.

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:763950 CAPLUS
DN 123:135764
TI Synthesis of new peptidyl imidazodithi(and -thiadi)azoles as potential fungicides.
AU Yadav, Lal Dhar S.; Shukla, Supriya
CS Department of Chemistry, University of Allahabad, Allahabad, 211 002, India
SO Journal of Agricultural and Food Chemistry (1995), 43(9), 2526-9
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
IT **165127-80-0P**
RL: AGR (Agricultural use); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation as fungicide)
RN 165127-80-0 CAPLUS

CN Glycine, N-[3-[(tetrahydro-7-oxo-6-phenyl-5-thioxoimidazo[1,5-b][1,4,2]dithiazol-2-ylidene)amino]benzoyl]- (9CI) (CA INDEX NAME)



IT **165127-84-4P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as fungicide)
RN 165127-84-4 CAPLUS
CN Glycine, N-[3-[(tetrahydro-5,7-dioxo-6-phenylimidazo[1,5-b][1,4,2]dithiazol-2-ylidene)amino]benzoyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB (4-Oxo-3-phenyl-2-thioxoimidazolidin-5-yl) N-aryldithiocarbamates, obtained by the reaction of 5-bromo-3-phenyl-2-thiohydantoin and ammonium N-aryldithiocarbamates, underwent chemoselective intramol. heterocyclizations with iodine and SOCl2 to yield 2-(arylimino)-6-phenyl-5-thioxoperhydroimidazo[1,5-d][1,3,4]dithiazole-7-thiones (I, m- or p-CO2H) and 3,6-diaryl-2,5-dithioxoperhydroimidazo[5,1-b][1,3,4]thiadiazol-7-ones (II), resp. I and II were converted into the corresponding 2- and 3-peptidyl derivs. III (R = H or Me) and IV (R = H or Me). III and IV on dethio-oxygenation furnished the corresponding diones V (R = H or Me) and VI (R = H or Me). Fungitoxicities of some compds. were evaluated in vitro against Alternaria solani and Fusarium oxysporum. Several compds. displayed activities comparable with that of Dithane M-45. Structure-activity relationships for the tested compds. are discussed.

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1985:103657 CAPLUS
DN 102:103657
TI Photothermographic color imaging process
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59174835	A2	19841003	JP 1983-48753	19830325
	JP 02051495	B4	19901107		
	US 5064742	A	19911112	US 1990-504068	19900329
				JP 1983-48753	19830325
				US 1984-592203	19840322

IT **94973-29-2**
RL: USES (Uses)
(color diffusion-transfer photothermog. coupler)

RN 94973-29-2 CAPLUS

CN Glycine, N-[3-[[4-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]thio]-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]amino]-4-chlorobenzoyl]- (9CI) (CA INDEX NAME)



GI



I

AB A photothermog. process is claimed in which a photosensitive sheet containing Ag halide, a hydrophilic binder, a reducing agent (for Ag halide), and a diffusion-resistant 2-equivalent coupler which forms a diffusible hydrophilic dye is imagewise exposed and developed to form diffusible dye images, and

the dye images are transferred onto a dye-mordanting layer at an elevated temperature in the presence of a hydrophilic low m.p. Thus, a polyester film support was coated with a composition containing gelatin and Me acrylate-trimethyl(vinylbenzyl)ammonium chloride copolymer and coated with a high temperature solvent composition containing urea, poly(vinyl alc.), p-C9H19C6H4O(CH2CH2O)8H, and Na dodecylbenzenesulfonate to give a receptor sheet. Sep., another film support was coated with a composition containing Ag(Br,Cl) emulsion, I, guanidine trichloroacetate, 2,6-dichloro-4-aminophenol and p-C9H19C6H4O(CH2CH2O)8H to give a photothermog. film. The film was imagewise exposed, heated at 130°, then contacted with the receptor sheet and heated at 120° to form clear magenta dye images on the receptor.

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1975:409777 CAPLUS
DN 83:9777
TI Iodine-substituted cyclic amidines as x-ray contrast agents
IN Obendorf, Werner; Schwarzinger, Ernst; Krieger, Josef; Lindner, Irmgard
PA Chemie Linz A.-G., Austria
SO Austrian, 7 pp.
CODEN: AUXXAK
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI AT 319226	B	19741210	AT 1972-6598	19720731
			AT 1972-6598	19720731

IT **55580-18-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55580-18-2 CAPLUS
CN Glycine, N-[2,4,6-triiodo-3-[[1-(2-methoxyethyl)-2-pyrrolidinylidene]amino]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

GI For diagram(s), see printed CA Issue.
AB Pyrrolidinylideneaminobenzoylaminopropionates I (R = Me, CH2CH2OH, CH2CH2OMe, H, Et, (CH2)3OMe, cyclohexyl, Ph, OMe; R1 = H, Me, allyl, CHMe2, Et, (CH2)3OMe; R2 = H, Me, Et; R3 = H, Me) and some related compds. (30 compds.) were prepared as contrast media for gallbladder radiog. Thus 106.6 g 2,4,6,3-I3(H2N)C6HCOCl was treated with 100 ml N-methylpyrrolidone

and 30.7 g of the product treated with 14.4 g MeNHCH2CHMeCO2Me to give 19 g I (R-R2 = Me, R3 = H).

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1975:160245 CAPLUS
DN 82:160245
TI X-ray contrast medium
IN Obendorf, Werner; Schwarzinger, Ernst; Krieger, Josef; Lindner, Irmgard
PA Chemie Linz A.-G.
SO Austrian, 7 pp.
CODEN: AUXXAK
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI AT 319463	B	19741227	AT 1972-6601	19720731
			AT 1972-6601	19720731

IT **52545-41-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52545-41-2 CAPLUS
CN Glycine, N-[2,4,6-triiodo-3-[[1-(2-methoxyethyl)-2-pyrrolidinylidene]amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI For diagram(s), see printed CA Issue.
AB I (X = CONR1, Y = a straight or branched alkylene or xy = y, R and R1 = H, alkyl, hydroxyalkyl, methoxyalkyl, cycloalkyl, aryl, or aralkyl) are useful contrast mediums of low toxicity and rapid clearance from the body. The pyrrolidine ring may be replaced by 3,4,5,6-tetrahydro-(2H)-azepine. For example, N-methyl-2-pyrrolidinone [872-50-4] and POCl3 are added to a solution of 3-amino-2,4,6-triiodobenzoyl chloride [51935-27-4] in CHCl3, and the mixture refluxed for 2 hr, to yield 3-(1-methyl-2-pyrrolidinylideneamino)-2,4,6-triiodobenzoyl chloride [52545-26-3]. A solution of this chloride and MeHNCH2CHMeCO2Me [21388-25-0] in CHCl3 was refluxed for 20 min. and the acid chloride hydrolyzed, to give I (XY = CONMeCH2CHMe, R = Me) [52545-27-4]. A tablet formulation was given for I(XY = CONHCH2CH2, R = MeOCH2CH2) [52545-31-0].

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1974:108358 CAPLUS
DN 80:108358
TI Cyclic amidines for x-ray contrast medium
IN Oberndorf, Werner; Lindner, Irmgard; Schwarzinger, Ernst; Krieger, Josef
PA Lentia G.m.b.H., Chem. u. Pharm. Erzeugnisse-Industriebedarf
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2235915	A1	19740207	DE 1972-2235915	19720721
	DE 2235915	B2	19760422		
	DE 2235915	C3	19761209		
	FI 56679	B	19791130	FI 1973-2021	19730621
	FI 56679	C	19800310		
				DE 1972-2235915	19720721
	CS 184331	P	19780831	CS 1973-4962	19730710
				DE 1972-2235915	19720721
	SE 393608	B	19770516	SE 1973-9733	19730711
				DE 1972-2235915	19720721
	GB 1393231	A	19750507	GB 1973-33383	19730712
				DE 1972-2235915	19720721
	ZA 7304789	A	19740626	ZA 1973-4789	19730713
				DE 1972-2235915	19720721
	HU 166462	P	19750328	HU 1973-OE204	19730713
				DE 1972-2235915	19720721
	CA 991191	A1	19760615	CA 1973-176494	19730716
				DE 1972-2235915	19720721
	DD 107909	Z	19740820	DD 1973-172323	19730717
				DE 1972-2235915	19720721
	DK 138580	C	19790305	DK 1973-3936	19730717
	DK 138580	B	19781002		
				DE 1972-2235915	19720721
	FR 2193620	A1	19740222	FR 1973-26276	19730718
				DE 1972-2235915	19720721
	CH 592451	A	19771031	CH 1973-10588	19730719
				DE 1972-2235915	19720721
	NL 7310135	A	19740123	NL 1973-10135	19730720
				DE 1972-2235915	19720721
	JP 49055658	A2	19740530	JP 1973-80759	19730720
	JP 53031866	B4	19780905		
				DE 1972-2235915	19720721
	US 3925412	A	19751209	US 1973-381336	19730720
				DE 1972-2235915	19720721
	IT 999524	A	19760310	IT 1973-69186	19730720
				DE 1972-2235915	19720721
	SU 528867	D	19760915	SU 1973-1948987	19730720
				DE 1972-2235915	19720721
	PL 89364	P	19761130	PL 1973-164197	19730720
				DE 1972-2235915	19720721
	RO 66797	B	19790616	RO 1973-84174	19730720
				DE 1972-2235915	19720721
	RO 66797	P	19800315	RO 1973-81174	19730720
				DE 1972-2235915	19720721
	ES 417137	A1	19760301	ES 1973-417137	19730721
				DE 1972-2235915	19720721

BE 806666	A1	19740429	BE 1973-137191	19731029
			FR 1973-26276	19730718
SU 578866	D	19771030	SU 1974-2074276	19741110
			DE 1972-2235915	19720721

IT **52545-41-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52545-41-2 CAPLUS
CN Glycine, N-[2,4,6-triiodo-3-[[1-(2-methoxyethyl)-2-pyrrolidinylidene]amino]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI For diagram(s), see printed CA Issue.
AB About twenty-eight cyclic amidines [I; R = carboxyalkyl or (carboxyalkyl)-carbamoyl; R1 = H Me, Et, (CH2)2OH, Ph, cyclohexyl, or (CH2)nOMe, n = 0, 2, or 3], useful as x-ray contrast medium especially for the cholecystog., were prepared by reaction of the pyrrolidinones II and POCl3 with III (R = carboxyalkyl) or with III (R = COCl) and subsequent reaction with an alkyl aminoalkanecarboxylate followed by saponification

=> d l7 fbib hitstr abs total

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:965163 CAPLUS
DN **138:39539**
TI Preparation of amino acid derivatives as inhibitors of protein isoprenyl transferases
IN Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Greg B.; Fakhoury, Stephen A.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Szczepankiewicz, Bruce G.; Gunawardana, Indrani W.
PA University of Pittsburgh, USA
SO U.S. Pat. Appl. Publ., 499 pp., Cont.-in-part of U.S. Ser. No. 852,858, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002193596	A1	20021219	US 2001-984411	20011030

	US 6693123	B2	20040217		
				US 1995-7247P	P 19951106
				US 1996-740909	B2 19961105
				US 1997-852858	B2 19970507

PATENT FAMILY INFORMATION:

FAN 1997:436061

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717070	A1	19970515	WO 1996-US17092	19961105
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-7247P	P 19951106
	AU 9675975	A1	19970529	AU 1996-75975	19961105
				US 1995-7247P	P 19951106
				WO 1996-US17092W	19961105
	ZA 9609273	A	19980505	ZA 1996-9273	19961105
				US 1995-7247P	P 19951106
	EP 873123	A1	19981028	EP 1996-938647	19961105
	EP 873123	B1	20030409		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1995-7247P	P 19951106
				WO 1996-US17092W	19961105
	JP 2000500745	T2	20000125	JP 1997-518208	19961105
				US 1995-7247P	P 19951106
				WO 1996-US17092W	19961105
	AT 236632	E	20030415	AT 1996-938647	19961105
				US 1995-7247P	P 19951106
				WO 1996-US17092W	19961105
	ES 2196186	T3	20031216	ES 1996-938647	19961105
				US 1995-7247P	P 19951106

FAN 1998:744940

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850029	A1	19981112	WO 1998-US9296	19980507
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1997-852858 A	19970507
	AU 9874733	A1	19981127	AU 1998-74733	19980507
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	EP 986384	A1	20000322	EP 1998-922122	19980507
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	JP 2002518985	T2	20020625	JP 1998-548480	19980507
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	TW 492955	B	20020701	TW 1998-87107182	19980715
				US 1997-852858 A	19970507
	MX 9910186	A	20000630	MX 1999-10186	19991105

				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507

FAN 1998:744941

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850030	A1	19981112	WO 1998-US9297	19980507
	W: CA, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1997-852858 A	19970507
	TW 492955	B	20020701	TW 1998-87107182	19980715
				US 1997-852858 A	19970507

FAN 1998:744942

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850031	A1	19981112	WO 1998-US9298	19980507
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1997-852858 A	19970507
	AU 9873719	A1	19981127	AU 1998-73719	19980507
				US 1997-852858 A	19970507
				WO 1998-US9298 W	19980507
	TW 492955	B	20020701	TW 1998-87107182	19980715
				US 1997-852858 A	19970507

FAN 2001:195207

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6204293	B1	20010320	US 1998-73807	19980507
				US 1995-7247P P	19951106
				US 1996-740909 B2	19961105
				US 1997-852858 B2	19970507

FAN 2001:297641

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6221865	B1	20010424	US 1998-73795	19980507
				US 1995-7247P P	19951106
				US 1996-740909 B2	19961105
				US 1997-852858 B2	19970507

FAN 2001:792340

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6310095	B1	20011030	US 1998-73794	19980507
				US 1995-7247P P	19951106
				US 1996-740909 B2	19961105
				US 1997-852858 B2	19970507
	ZA 9906763	A	20000515	ZA 1999-6763	19991027
				US 1998-73794 A	19980507
				US 1998-197279 A	19981120

OS MARPAT 138:39539

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is L4-NR5-L5, L4-O-L5, L4-S(O)m-L5, etc., where L4 and L5 are absent or alk(en)ylene, R5 is H, alkanoyl, alkoxy, alkoxyalkyl, etc.;

m = 0-2; Z is a covalent bond, O, S(O)m, an imino group; R3 = (un)substituted pyridyl or imidazolyl; or L1, Z, and R3 together are aminoalkyl, haloalkyl, halo, carboxaldehyde, (carboxaldehyde)alkyl, or hydroxyalkyl (R1 ≠ H) or L1, Z, R3, and R4 together are an (un)substituted pyrrolidinone ring] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-(3-pyridylcarbonylamino)-2-phenylbenzoyl]methionine hydrochloride, prepared via amidation reaction, showed 93% inhibition of farnesyl transferase at 1x10-5 M.

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:791912 CAPLUS
DN **135:344503**
TI Preparation of imidazopyrimidines and triazolopyrimidines as inhibitors of Syk tyrosine kinase
IN Yura, Takeshi; Conception, Arnel B.; Hahn, Kyun Hee; Hiraoka, Makiko; Katsumada, Hiroko; Kawamura, Norihiro; Kokubo, Toshio; Komura, Hiroshi; Lee, Young Ho; Lowinger, Timothy B.; Motegi, Munehito; Yamamoto, Tomoyuki; Yoshida, Osahiro
PA Bayer A.-G., Germany
SO Jpn. Kokai Tokkyo Koho, 212 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001302667	A2	20011031	JP 2000-128870	20000428
WO 2001083485	A1	20011108	WO 2001-EP4357	20010417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			JP 2000-128870 A	20000428
EP 1278750	A1	20030129	EP 2001-936242	20010417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417
BR 2001010404	A	20030211	BR 2001-10404	20010417
			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417
JP 2003535067	T2	20031125	JP 2002-500795	20010417
			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417
BG 107166	A	20030630	BG 2002-107166	20021003
			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417
NO 2002005154	A	20021025	NO 2002-5154	20021025
			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417
US 2004054179	A1	20040318	US 2003-258628	20030214
			JP 2000-128870 A	20000428
			WO 2001-EP4357 W	20010417

OS MARPAT 135:344503

GI



I

AB The title compds. [I; R1 = X-R4, (un)substituted 4- to 5-membered (un)saturated heterocyclyl containing ≤4 heteroatoms selected from O, N, and S, 4 to 7-membered (un)saturated carbocyclyl, 7 to 10-membered (un)saturated condensed ring moiety optionally containing ≤4 heteroatoms selected from O, N, and S [wherein X = (un)substituted CH2, O, S, SO, SO2, (un)substituted NH; R4 = (un)substituted C7-10 aroyl, C7-10 aralkyl, C1-10 alkyl, C2-10 alkenyl, C3-7 (un)saturated carbocyclyl, 4 to 7-membered (un)saturated heterocyclyl containing ≤4 heteroatoms selected from O, N, and S, 7 to 10-membered (un)saturated condensed ring moiety optionally containing ≤4 heteroatoms selected from O, N, and S]; Y = CH, N; R2 = H, (un)substituted C1-10 alkyl, NR8COR9, NR8CO2R9, COR8, CO2R9, CONR8R9 [wherein R8, R9 = H, (un)substituted C1-6 alkyl]; R3 = (un)substituted aryl or heteroaryl] or salts thereof are prepared These compds. are useful as antiallergic agent for the prevention or treatment of asthma, allergic rhinitis, atopic dermatitis, food allergy, contact allergy, hives, conjunctivitis, and vernal (spring) catarrh, or as immunosuppressants, anticoagulants, or antitumor agents. Thus, 5-chloro-7-(3,4-dimethoxyphenyl)imidazo[1,2-c]pyrimidine, 1-(4-fluorophenyl)piperazine dihydrochloride, diisopropylethylamine, and 2-propanol were heated at 90° with stirring to give 64.6% 7-(3,4-dimethoxyphenyl)-5-[4-(4-fluorophenyl)piperazin-1-yl]imidazo[1,2-c]pyrimidine which showed IC50 of ≤0.5 μM against Syk tyrosine kinase.

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:842104 CAPLUS
DN **134:29204**
TI Preparation of benzamidines and arylamidines as inhibitors of factor Xa
IN Zhu, Bing-Yan; Zhang, Penglie; Scarborough, Robert M.
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000071508	A2	20001130	WO 2000-US14208	20000524

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 1999-135849PP 19990524

EP 1185508 A2 20020313 EP 2000-932732 20000524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 1999-135849PP 19990524
WO 2000-US14208W 20000524

JP 2003500383 T2 20030107 JP 2000-619765 20000524
US 1999-135849PP 19990524
WO 2000-US14208W 20000524

US 6638980 B1 20031028 US 2000-576633 20000524
US 1999-135849PP 19990524

PATENT FAMILY INFORMATION:

FAN 2000:842106

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071510	A2	20001130	WO 2000-US14195	20000524
	WO 2000071510	A3	20010830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 1999-135849PP 19990524

EP 1183235 A2 20020306 EP 2000-937700 20000524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 1999-135849PP 19990524
WO 2000-US14195W 20000524

JP 2003500385 T2 20030107 JP 2000-619767 20000524
US 1999-135849PP 19990524
WO 2000-US14195W 20000524

US 6638980 B1 20031028 US 2000-576633 20000524
US 1999-135849PP 19990524

FAN 2000:842107

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071511	A2	20001130	WO 2000-US14205	20000524
	WO 2000071511	A3	20010809		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 1999-135849PP 19990524

EP 1185509 A2 20020313 EP 2000-942640 20000524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 1999-135849PP 19990524

				WO 2000-US14205W 20000524
	JP 2003500386	T2	20030107	JP 2000-619768 20000524
				US 1999-135849PP 19990524
				WO 2000-US14205W 20000524
	US 6638980	B1	20031028	US 2000-576633 20000524
				US 1999-135849PP 19990524

OS MARPAT 134:29204
GI



I

AB AYDEGJZL [wherein A = (cyclo)alkyl, (un)substituted amino, imino, amidino, guanidino, Ph, naphthyl, heterocyclic ring, etc.; Y = bond, CH2, CO, NR4CH2, CH2NR4, NR4, CONR4, NR4CO, C(:NR4), C(:N4)NR4a, C(:NR4)CH2, C(:NR4)NR4aCH2, SO2, O, SO2NR4, or NR4SO2; R4 and R4a = independently H, alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl, or (un)substituted alklylphenyl or aklynaphthyl; D = bond, (un)substituted Ph, naphthyl, or heterocyclic ring; E = NR5CO, NR5CONR6, SO2NR5, NR5SO2NR6, NR5SO2NR6CO; R5 and R6 = H, alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl or (un)substituted alkylphenyl, alkylnaphthyl, alkylheteroaryl, carboxyalkyl, carbamidoalkyl, etc.; G = (un)substituted methylene, ethylene, or propylene; J = bond, CONR11, NR11CO, NR11, NR11CH2, O, S, SO2, SO, OCH2, or SO2CH2; R11 = H, alkyl, alkenyl, alkynyl, (alkyl)cycloalkyl or (un)substituted alkylphenyl, alkylnaphthyl, or alkylheteroary; Z = (un)substituted Ph, naphthyl, or heterocyclic ring; L = H, CN, CONR12NR13, (CH2)0-2NR12R13, C(:NR12)NR12R13, NR12R13, OR12, NR12C(:NR12)NR12N13, or NR12C(:N12)R13; R12 and R13 = independently H, OH, alkyl, (un)substituted alkoxy, (di)alkylamino, alkylphenyl, alkylnaphthyl, carboxyalkyl, etc.] were prepared as potent and highly selective inhibitors of factor Xa for the prevention or treatment of coagulation disorders (no data). For example, N-tert-butoxycarbonylglycinol was condensed with 3-cyanophenol in the presence of PPh3 and DEAD in CH2Cl2 (93%), and the amine deprotected and converted to the salt using TFA. Reaction of the TFA amine salt with 2'-(tert-butylaminosulfonyl)-4-biphenylcarboxylic acid in the presence of BOP and i-Pr2NEt in DMF gave the amide (84%). The benzonitrile was converted to the desired benzamidine salt (I•TFA) in 85% yield by bubbling HCl gas through a solution of the amide intermediate in MeOH, followed by neutralization and workup using 0.5% TFA in H2O/MeCN. Compds. of the invention show selectivity for factor Xa vs. other proteases of the coagulation cascade or the fibrinolytic cascade, and are useful as diagnostic reagents as well as antithrombotic agents (no data).

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:744940 CAPLUS
DN **130:25338**
TI Inhibitors of protein isoprenyl transferases

IN Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; Tasker, Andrew S.; Wasick, James I.; Winn, Martin

PA University of Pittsburgh, USA

SO PCT Int. Appl., 848 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850029	A1	19981112	WO 1998-US9296	19980507
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1997-852858 A	19970507
	AU 9874733	A1	19981127	AU 1998-74733	19980507
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	EP 986384	A1	20000322	EP 1998-922122	19980507
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	JP 2002518985	T2	20020625	JP 1998-548480	19980507
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507
	TW 492955	B	20020701	TW 1998-87107182	19980715
				US 1997-852858 A	19970507
	MX 9910186	A	20000630	MX 1999-10186	19991105
				US 1997-852858 A	19970507
				WO 1998-US9296 W	19980507

PATENT FAMILY INFORMATION:

FAN 1997:436061

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717070	A1	19970515	WO 1996-US17092	19961105
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-7247P P	19951106
	AU 9675975	A1	19970529	AU 1996-75975	19961105
				US 1995-7247P P	19951106
				WO 1996-US17092W	19961105
	ZA 9609273	A	19980505	ZA 1996-9273	19961105
				US 1995-7247P P	19951106
	EP 873123	A1	19981028	EP 1996-938647	19961105
	EP 873123	B1	20030409		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1995-7247P P	19951106

				WO 1996-US17092W 19961105
	JP 2000500745	T2	20000125	JP 1997-518208 19961105
				US 1995-7247P P 19951106
				WO 1996-US17092W 19961105
	AT 236632	E	20030415	AT 1996-938647 19961105
				US 1995-7247P P 19951106
				WO 1996-US17092W 19961105
	ES 2196186	T3	20031216	ES 1996-938647 19961105
				US 1995-7247P P 19951106

FAN 1998:744941

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 9850030	A1	19981112	WO 1998-US9297 19980507
	W: CA, JP, MX			
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
				US 1997-852858 A 19970507
	TW 492955	B	20020701	TW 1998-87107182 19980715
				US 1997-852858 A 19970507

FAN 1998:744942

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 9850031	A1	19981112	WO 1998-US9298 19980507
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
				US 1997-852858 A 19970507
	AU 9873719	A1	19981127	AU 1998-73719 19980507
				US 1997-852858 A 19970507
				WO 1998-US9298 W 19980507
	TW 492955	B	20020701	TW 1998-87107182 19980715
				US 1997-852858 A 19970507

FAN 2001:195207

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 6204293	B1	20010320	US 1998-73807 19980507
				US 1995-7247P P 19951106
				US 1996-740909 B219961105
				US 1997-852858 B219970507

FAN 2001:297641

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 6221865	B1	20010424	US 1998-73795 19980507
				US 1995-7247P P 19951106
				US 1996-740909 B219961105
				US 1997-852858 B219970507

FAN 2001:792340

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 6310095	B1	20011030	US 1998-73794 19980507
				US 1995-7247P P 19951106
				US 1996-740909 B219961105
				US 1997-852858 B219970507

	ZA 9906763	A	20000515	ZA 1999-6763	19991027
				US 1998-73794 A	19980507
				US 1998-197279 A	19981120

FAN 2002:965163

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193596	A1	20021219	US 2001-984411	20011030
	US 6693123	B2	20040217		
				US 1995-7247P P	19951106
				US 1996-740909 B2	19961105
				US 1997-852858 B2	19970507

OS MARPAT 130:25338

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4NR5L5, L4OL5, L4S(O)mL5 (m = 0-2), etc., where L4 and L5 are absent or alkylene, alkenylene, R5 is H, alkanoyl; Z is a covalent bond, O, S(O)q (q = 0-2), NH or imino; R3 = H, aryl, fluorenyl, heterocyclyl, cycloalkyl, etc.] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:250700 CAPLUS

DN **128:295059**

TI Preparation of pyridyl- and naphthyridylalkoxybenzoyl-α-(phenylsulfonylamino)-β-alanine derivatives and analogs for inhibiting osteoclast-mediated bone resorption

IN Hartman, George D.; Duggan, Mark E.; Hoffman, William F.; Ihle, Nathan C.

PA Merck and Co., Inc., USA

SO U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 250,218, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5741796	A	19980421	US 1996-714097	19960926
				US 1994-250218 B2	19940527
				WO 1995-US5938 W	19950512
	WO 9532710	A1	19951207	WO 1995-US5938	19950512
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1994-250218 A	19940527
	US 5929120	A	19990727	US 1998-15982	19980130
				US 1994-250218 B2	19940527
				US 1996-714097 A3	19960926

PATENT FAMILY INFORMATION:

FAN 1996:181547

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9532710	A1	19951207	WO 1995-US5938	19950512

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

			US 1994-250218 A 19940527
CA 2190870	AA	19951207	CA 1995-2190870 19950512
			US 1994-250218 A 19940527
AU 9525868	A1	19951221	AU 1995-25868 19950512
AU 701776	B2	19990204	
			US 1994-250218 A 19940527
			WO 1995-US5938 W 19950512
EP 760658	A1	19970312	EP 1995-920409 19950512
EP 760658	B1	20021113	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
			US 1994-250218 A 19940527
			WO 1995-US5938 W 19950512
JP 10501222	T2	19980203	JP 1995-500899 19950512
			US 1994-250218 A 19940527
			WO 1995-US5938 W 19950512
AT 227567	E	20021115	AT 1995-920409 19950512
			US 1994-250218 A 19940527
			WO 1995-US5938 W 19950512
ES 2186720	T3	20030516	ES 1995-920409 19950512
			US 1994-250218 A 19940527
US 5741796	A	19980421	US 1996-714097 19960926
			US 1994-250218 B219940527
			WO 1995-US5938 W 19950512

OS MARPAT 128:295059
GI



I



II

AB Compds. of structure I [X = various amino, amidino, guanidino, and N-heterocyclic groups; Y = alkylene, alkynylene, alkenylene, etc.; B = alkylene with optional amide moiety in chain; R1 = H, alkoxyalkyl, alkoxycarbonylalkyl, (di)(alkyl)aminoalkyl, aralkyl; R6, R7 = H, (di)alkylaminoalkyl, alkoxycarbonylaminoalkyl, alkylsulfonylaminoalkyl, alkylcarbonylaminoalkyl; R12 = OH, alkoxy, dialkylaminocarbonylmethoxy, aryldialkylaminocarbonylmethoxy; with provisos], are described which

inhibit osteoclast-mediated bone resorption. Specifically, the compds. are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compds. may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions. Syntheses of approx. 50 compds. in 37 synthetic examples are described. Thus, amidation of Me 4-[2-(4-aminopyridin-6-yl)ethoxy]benzoic acid (preparation given) with (R)-H2NCH2CH(NHSO2Ph)CO2CMe3.HCl (preparation given)
using EDC, N-hydroxybenzotriazole (HOBt), and N-methylmorpholine in DMF, followed by deprotection with CF3CO2H gave desired compound II. In EIB and OCFORM assays, prepared compds. I had values ranging 0.5-500 nM and 1-1000 nM, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:769193 CAPLUS
DN **128:88933**
TI Preparation of triazine-containing anionic compounds and their use as antiviral agents
IN Gluzman, Yakov; Larocque, James Paul; O'Hara, Bryan Mark; Morin, John Edward; Ellestad, George Alfred; Mitsner, Boris; Ding, Wei Dond; Raifekd, Yuri Efimovich; Nikitenko, Antonina Aristotelev
PA American Cyanamid Co., Japan
SO Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09309882	A2	19971202	JP 1997-28029	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	US 5852015	A	19981222	US 1997-789038	19970127
	SK 282598	B6	20021008	SK 1997-179	19970206
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NO 9700652	A	19970814	NO 1997-652	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CA 2197394	AA	19980727	CA 1997-2197394	19970212
				US 1997-789038 A	19970127
	IL 120206	A1	20000217	IL 1997-120206	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	RU 2170731	C2	20010720	RU 1997-102335	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CZ 290450	B6	20020717	CZ 1997-423	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NZ 328399	A	20010427	NZ 1997-328399	19970723
				US 1997-789038 A	19970127

PATENT FAMILY INFORMATION:
FAN 1997:632410

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 795549	A1	19970917	EP 1997-300905	19970212
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	US 5852015	A	19981222	US 1997-789038	19970127
	SK 282598	B6	20021008	SK 1997-179	19970206
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NO 9700652	A	19970814	NO 1997-652	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CA 2197394	AA	19980727	CA 1997-2197394	19970212
				US 1997-789038 A	19970127
	IL 120206	A1	20000217	IL 1997-120206	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	RU 2170731	C2	20010720	RU 1997-102335	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CZ 290450	B6	20020717	CZ 1997-423	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NZ 328399	A	20010427	NZ 1997-328399	19970723
				US 1997-789038 A	19970127

FAN 1997:776761

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2197393	AA	19970814	CA 1997-2197393	19970212
				US 1996-11542P P	19960213
	CN 1163890	A	19971105	CN 1997-104706	19970212
	CN 1062860	B	20010307		
				US 1996-11542P P	19960213
	ZA 9701185	A	19980812	ZA 1997-1185	19970212
				US 1996-11542P P	19960213
	BR 9700939	A	19980901	BR 1997-939	19970212
				US 1996-11542P P	19960213
	AU 9714704	A1	19970821	AU 1997-14704	19970213
				US 1996-11542P P	19960213
	NZ 314225	A	20010330	NZ 1997-314225	19970213
				US 1996-11542P P	19960213
	TW 438797	B	20010607	TW 1997-86101818	19970213
				US 1996-11542P P	19960213
	AU 9734190	A1	19971030	AU 1997-34190	19970814
	AU 710536	B2	19990923		
				US 1996-11542P P	19960213

OS MARPAT 128:88933
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The compds. I [A = II, III, IV, V, VI, VII; R = SO3H, OSO3H, OH, CO2H; B = NH, NR1; R1 = C1-6 alkyl which may be substituted with Cl, Br, F, OH, cyano; X = Cl, F, VIII; U = SO2, CO, NCO, NCS; W = N(YZ)2, IX, X; Y = C(CH2)n; n = 0-6; m = 0-2; Z = H, Me, CF3, CH2X, CH2OH, CO2H, C1-6

alkoxycarbonyl, CONR22, cyano, CHR2OH; X = Cl, Br, F, I; R2 = H, C1-6 alkyl], their salts, or their esters are claimed. Also claimed are pharmaceutical compns. containing ≥1 I, their salts, or their esters for treatment of infection with respiratory syncytial virus (RSV), herpes simplex virus, HIV virus, cytomegalovirus, and influenza virus. 4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)sulfonylimino]-1,3,5-triazin-2-ylamino]stilbene-2,2'-disulfonic acid, prepared from cyanuric chloride, 4,4'-diaminostilbene-2,2'-disulfonic acid, and 3-aminophenyl-N,N-bis(2-carbamoylethyl)sulfonylimine, inhibited plaque formation of RSV in Vero cells at IC50 0.1 μg/mL. A small-particle aerosol of this compound also showed antiviral effect on cotton rats infected with RSV.

L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:632410 CAPLUS
DN **127:307402**
TI Preparation of bis-aryloxy(amino)-triazinyl-oxy(amino)aryl derivatives as antiviral agents
IN Gluzman, Yakov; Larocque, James Paul; O'Hara, Bryan Mark; Morin, John Edward; Ellestad, George Alfred; Mitsner, Boris; Ding, Wei-Dong; Raifeld, Yuri Efimovich; Nikitenko, Antonina Aristotelev
PA American Cyanamid Company, USA
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 795549	A1	19970917	EP 1997-300905	19970212
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	US 5852015	A	19981222	US 1997-789038	19970127
	SK 282598	B6	20021008	SK 1997-179	19970206
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NO 9700652	A	19970814	NO 1997-652	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CA 2197394	AA	19980727	CA 1997-2197394	19970212
				US 1997-789038 A	19970127
	IL 120206	A1	20000217	IL 1997-120206	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	RU 2170731	C2	20010720	RU 1997-102335	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	CZ 290450	B6	20020717	CZ 1997-423	19970212
				US 1996-11542P P	19960213
				US 1997-789038 A	19970127
	NZ 328399	A	20010427	NZ 1997-328399	19970723
				US 1997-789038 A	19970127

PATENT FAMILY INFORMATION:
FAN 1997:769193

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09309882	A2	19971202	JP 1997-28029	19970212

				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	US 5852015	A	19981222	US 1997-789038 19970127
	SK 282598	B6	20021008	SK 1997-179 19970206
				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	NO 9700652	A	19970814	NO 1997-652 19970212
				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	CA 2197394	AA	19980727	CA 1997-2197394 19970212
				US 1997-789038 A 19970127
	IL 120206	A1	20000217	IL 1997-120206 19970212
				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	RU 2170731	C2	20010720	RU 1997-102335 19970212
				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	CZ 290450	B6	20020717	CZ 1997-423 19970212
				US 1996-11542P P 19960213
				US 1997-789038 A 19970127
	NZ 328399	A	20010427	NZ 1997-328399 19970723
				US 1997-789038 A 19970127

FAN 1997:776761

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	CA 2197393	AA	19970814	CA 1997-2197393 19970212
				US 1996-11542P P 19960213
	CN 1163890	A	19971105	CN 1997-104706 19970212
	CN 1062860	B	20010307	
				US 1996-11542P P 19960213
	ZA 9701185	A	19980812	ZA 1997-1185 19970212
				US 1996-11542P P 19960213
	BR 9700939	A	19980901	BR 1997-939 19970212
				US 1996-11542P P 19960213
	AU 9714704	A1	19970821	AU 1997-14704 19970213
				US 1996-11542P P 19960213
	NZ 314225	A	20010330	NZ 1997-314225 19970213
				US 1996-11542P P 19960213
	TW 438797	B	20010607	TW 1997-86101818 19970213
				US 1996-11542P P 19960213
	AU 9734190	A1	19971030	AU 1997-34190 19970814
	AU 710536	B2	19990923	
				US 1996-11542P P 19960213

OS MARPAT 127:307402
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = II, III, etc.; C' = SO3H, OSO3H, OH, COOH; B' = NH, NH, N(C1-6 alkyl); X = Cl, F, IV; U' = SO2, CO, NC(O), NC(S); W' = N(YZ), V, VI; Y = (CH2)n; n = 0-6; m = 0-2; Z = H, CH3, CF3, etc.] and their salts, useful as pharmaceuticals, especially for treating viral infections, particularly infections by respiratory syncytial virus, herpes simplex virus, human immunodeficiency virus, and cytomegalovirus, were prepared Thus, reaction of cyanuric chloride with 4,4'-diaminostilbene-2,2'-

disulfonic acid in the presence of NaOH in dioxane/phosphate buffer solution followed by addition of 3-aminophenyl-N,N-bis(2-carbamoylethyl)sulfonylimine in DMSO afforded 72% I.2Na+ {A = II; C' = H; B' = NH; X = IV; U'W' = 3-SO2N[(CH2)2CONH2]2} which showed IC50 of 0.3 μG/mL against respiratory syncytial virus growth.

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:425672 CAPLUS
DN **125:117384**
TI Reactive dyes containing 5-cyano-2,4- or -4,6-dichloropyrimidyl groups and their use
IN Auerbach, Guenther; Doerr, Markus; Doswald, Paul; Gisler, Markus; Koch, Werner; Moser, Helmut A.; Wald, Roland
PA Sandoz Ltd., Switz.
SO U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 627,168, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5527886	A	19960618	US 1992-899570	19920616
				US 1992-899570 A	19920616
				DE 1989-3941620B2	19891216
				US 1990-627168	19901214

PATENT FAMILY INFORMATION:
FAN 1992:153821

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2239024	A1	19910619	GB 1990-26925	19901212
	GB 2239024	B2	19930421		
				DE 1989-3941620A	19891215
	DE 4039866	A1	19910620	DE 1990-4039866	19901213
	DE 4039866	C2	20031030		
				DE 1989-3941620A1	19891216
	FR 2655994	A1	19910621	FR 1990-15751	19901213
	FR 2655994	B1	19971017		
				DE 1989-3941620A	19891216
	ES 2027869	A6	19920616	ES 1990-3193	19901213
				DE 1989-3941620A	19891216
	CH 681984	A	19930630	CH 1990-3970	19901214
				DE 1989-3941620A	19891216
	JP 06220348	A2	19940809	JP 1990-417742	19901217
	JP 2955373	B2	19991004		
				DE 1989-3941620A	19891216
	BR 9100491	A	19920922	BR 1991-491	19910206
				DE 1989-3941620	19891216

OS MARPAT 125:117384
AB Fiber-reactive compds. of the formula XO2SZ1QZ2NR1R2, and water-soluble salts thereof each cation of which is independently a non-chromophoric cation, and mixts. of such compds. or water-soluble salts, wherein Q is a chromophore-containing radical of a monoazo, disazo, polyazo, formazan, anthraquinone, dioxazine, phenazine, or azomethine dye, which is in metal-free or metal complex form, each of Z1 and Z2 is independently a direct bond or a bridging group which is attached to a carbon atom of an aromatic carbocyclic ring or to a carbon or nitrogen atom of an aromatic heterocyclic ring present in Q, X is vinyl or C2-4-alkylene-Y, wherein Y is hydroxy or a group which can be split off under alkaline conditions, R1 is

H, C1-4-alkyl optionally monosubstituted by hydroxy, halo, cyano, sulfo, ,sulfato, or carboxy, and Z is the title group are obtained for dyeing or printing hydroxyl- or nitrogen-containing substrates. The reactive dyes have good application and fastness properties. Thus, 4-aminophenyl 2-sulfatoethyl sulfone→6-hydroxyl-4-methyl-1-[3-(methylamino)propyl]-2-pyridone was prepared and condensed with 5-cyano-2,4,6-trichloropyrimidine to give a reactive dye which was fast greenish yellow on cotton.

L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:313785 CAPLUS
DN **124:336875**
TI Contrast media for liver imaging
IN Krause, Werner; Speck, Ulrich
PA Schering A.-G., Germany
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9603155	A1	19960208	WO 1995-EP2902	19950721
W: AU, BY, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			DE 1994-4426439	19940726
DE 4426439	C1	19960229	DE 1994-4426439	19940726
AU 9531163	A1	19960222	AU 1995-31163	19950721
			DE 1994-4426439	19940726
			WO 1995-EP2902	19950721
EP 773798	A1	19970521	EP 1995-926971	19950721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			DE 1994-4426439	19940726
			WO 1995-EP2902	19950721
JP 10502936	T2	19980317	JP 1995-505460	19950721
			DE 1994-4426439	19940726
			WO 1995-EP2902	19950721
ZA 9506226	A	19960314	ZA 1995-6226	19950726
			DE 1994-4426439	19940726

OS MARPAT 124:336875
AB The invention concerns the use of a compound comprising at least one halogenated, preferably iodated and most preferably tri-iodated, aromatic compds., for use in imaging the liver with synchrotron radiation, approx. monochromatic x-rays, or x-rays of below a certain wavelength.

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:227097 CAPLUS
DN **122:3567**
TI Safened salicylic acid derivative herbicides.
IN Bratz, Matthias; Vogelbacher, Uwe Josef; Rheinheimer, Joachim; Baumann, Ernst; Landes, Andreas; Walter, Helmut
PA BASF A.-G., Germany
SO Ger. Offen., 34 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4310220	A1	19941006	DE 1993-4310220	19930330
	WO 9422310	A1	19941013	WO 1994-EP862	19940318
	W: AU, CA, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1993-4310220	19930330
	AU 9464280	A1	19941024	AU 1994-64280	19940318
				DE 1993-4310220	19930330
				WO 1994-EP862	19940318

OS MARPAT 122:3567
GI



AB The salicylic acid derivative herbicides I and II [Z = N, CH; Y = O, S, (un)substituted NH; X = O, NR5, NOR5, NNHR5, NNR52; R = Cl, (un)substituted alkyl, alkynyl, alkenyl, etc.; R1 = H, alkyl, succinyliminooxy, etc.; R2,R3 = halo, (halo)alkyl, alkoxy, etc.;R4 = H; RR4 = 1,3-butadien-1,4-yl; R5 = H, alkyl, alkenyl, etc.] are safened with X1aC6H4WCOZ1 or III [X1 = H, NO2, halo, (halo)alkyl, alkoxy; Y1 = NO2, halo, (halo)alkyl, alkoxy; Z1 = (un)substituted OH, SH, NH2; W = divalent 5-membered heterocyclyl; R5 = (alkyl)alkylene; a,b = 1-5]. Thus, the phytotoxicity of I (R = Cl, R1 = ON:CMe2, R2 = R3 = OMe, R4 = H, X = O, Z = CH, Y = S) to barley was alleviated by Et 1-(2,4-dichlorophenyl)-5-isopropylpyrazol-3-ylcarboxylate.

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:509397 CAPLUS
DN **121:109397**
TI Preparation of ester derivatives of 4-azasteroids as steroid 5α-reductase inhibitors.
IN Witzel, Bruce E.; Rasmusson, Gary H.; Tolman, Richard L.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9323041	A1	19931125	WO 1993-US4771	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886022 A219920520	
	AU 9342525	A1	19931213	AU 1993-42525	19930519
	AU 668181	B2	19960426		
				US 1992-886022 A 19920520	
				WO 1993-US4771 A 19930519	
	EP 649306	A1	19950426	EP 1993-911362	19930519
	EP 649306	B1	20010110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1992-886022 A 19920520	
				WO 1993-US4771 W 19930519	
	JP 07508039	T2	19950907	JP 1993-503838	19930519
				US 1992-886022 A 19920520	
				WO 1993-US4771 W 19930519	
	AT 198601	E	20010115	AT 1993-911362	19930519
				US 1992-886022 A 19920520	
				WO 1993-US4771 W 19930519	
	US 5610162	A	19970311	US 1994-338573	19941117
				US 1992-886022 B219920520	
				WO 1993-US4771 W 19930519	

PATENT FAMILY INFORMATION:

FAN 1997:204394

PI	US 5610162	A	19970311	US 1994-338573	19941117
				US 1992-886022 B219920520	
				WO 1993-US4771 W 19930519	
	WO 9323041	A1	19931125	WO 1993-US4771	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886022 A219920520	

OS MARPAT 121:109397

GI



I

AB Title compds. [I; a, b = single bonds, R2 = H; or a = single bond, b =

double bond, and R2 = null; R1 = H, aryl, alkyl, aralkyl; R3 = H, Me, Et, OH, NH2, SMe; n = 0-10; X = O, S; R4 = (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, amino, OH, etc.] were prepared as inhibitors of 5α-reductase and isoenzymes thereof. The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp (no data). Thus, 20-hydroxy-4-methyl-5α-4-azapregnan-3-one, 11-ethylthioundecanoic acid, DMAP, and DCC were stirred in CH2Cl2 at room temperature to give 20-[11-(ethylthio)undecanoyloxy]-4-methyl-5α-4-azapregnan-3-one.

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245602 CAPLUS
DN **120:245602**
TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886031 A2	19920520
	AU 9342521	A1	19931213	AU 1993-42521	19930519
	AU 668180	B2	19960426		
				US 1992-886031 A	19920520
				WO 1993-US4746 A	19930519
	EP 641204	A1	19950308	EP 1993-911358	19930519
	EP 641204	B1	20000816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1992-886031 A	19920520
				WO 1993-US4746 W	19930519
	JP 07508038	T2	19950907	JP 1993-503831	19930519
				US 1992-886031 A	19920520
				WO 1993-US4746 W	19930519
	AT 195530	E	20000915	AT 1993-911358	19930519
				US 1992-886031 A	19920520
				WO 1993-US4746 W	19930519
	ES 2148229	T3	20001016	ES 1993-911358	19930519
				US 1992-886031 A	19920520
	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B2	19920520
				WO 1993-US4746 W	19930519

PATENT FAMILY INFORMATION:
FAN 1996:469929

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B2	19920520
				WO 1993-US4746 W	19930519

WO 9323040 A1 19931125 WO 1993-US4746 19930519
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 1992-886031 A219920520

OS MARPAT 120:245602
GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepared as inhibitors of steroid 5α-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5α-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5α-4-azaandrostan-3-one.

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:428157 CAPLUS
DN **119:28157**
TI Preparation of 4-oxoquinazolines and triazolines as herbicides
IN Barton, John Edward Duncan; Cartwright, David
PA Imperial Chemical Industries PLC, UK
SO Brit. UK Pat. Appl., 29 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2257970	A1	19930127	GB 1992-15645	19920723
			GB 1991-16207	19910726

OS MARPAT 119:28157
GI



I



II

AB Title compds. [I; B = N, CR2; E = CR3R4XR5; R = (hetero)aryl; W = O, NR1; R1 = H, alkyl; R2 = H, (halo)alkyl, halo, cyano, etc.; R3, R4 = halo, alkyl, alkenyl, NH2, etc.; R5 = CO2H, alkoxycarbonyl, CONH2, cyano, CH2OH, etc.; X = (CH2)n, CH:CH, CH(OH)CH2, COCH2, etc.; n = 0-2] were prepared Thus, 2-amino-5-(2-chloro-4-trifluoromethylphenoxy)benzamide was cyclocondensed with (CF3CO)2O and the product N-alkylated with ICH2CO2Et to give title compound II which gave 90-100% control of 5 weeds, e.g., Abutilon theophrasti, with no damage to rice or winter wheat at 0.25 kg/ha postemergent.

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:13416 CAPLUS
DN **116:13416**
TI Pressure- and heat-sensitive recording materials with good sensitivity, storability and image stability
IN Sano, Masajiro; Takashima, Masanobu; Satomura, Masato
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03142277	A2	19910618	JP 1989-282319	19891030
				JP 1989-282319	19891030

OS MARPAT 116:13416
AB The title materials utilizes coloration by contact between electron-donating leuco dye Ar1R1CH:CR2:CH:CHR3CR4R5Ar2 (Ar1, Ar2 = amine residue-containing aryl or heterocyclic group; R1-4 = H, monovalent group; R5 = aryl group-containing alkoxy group; R1-4 may bond together forming 4- to 12-membered rings with or without containing heteroatom) and electron-accepting compound

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	137.50	560.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.25	-15.25

STN INTERNATIONAL LOGOFF AT 10:51:26 ON 28 APR 2004